Full Text of SB1987 103rd General Assembly
SB1987 103RD GENERAL ASSEMBLY |
| | 103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024 SB1987 Introduced 2/9/2023, by Sen. Julie A. Morrison SYNOPSIS AS INTRODUCED: |
| 720 ILCS 570/102 | from Ch. 56 1/2, par. 1102 | 720 ILCS 570/204 | from Ch. 56 1/2, par. 1204 | 720 ILCS 570/206 | from Ch. 56 1/2, par. 1206 | 720 ILCS 570/210 | from Ch. 56 1/2, par. 1210 |
|
Amends the Illinois Controlled Substances Act. Reschedules various Schedule I and Schedule IV controlled substances. Defines "isomer".
|
| |
| | A BILL FOR |
|
| | | SB1987 | | LRB103 25792 RLC 57149 b |
|
| 1 | | AN ACT concerning criminal law.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Sections 102, 204, 206, and 210 as | 6 | | follows: | 7 | | (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) | 8 | | Sec. 102. Definitions. As used in this Act, unless the | 9 | | context
otherwise requires:
| 10 | | (a) "Addict" means any person who habitually uses any | 11 | | drug, chemical,
substance or dangerous drug other than alcohol | 12 | | so as to endanger the public
morals, health, safety or welfare | 13 | | or who is so far addicted to the use of a
dangerous drug or | 14 | | controlled substance other than alcohol as to have lost
the | 15 | | power of self control with reference to his or her addiction.
| 16 | | (b) "Administer" means the direct application of a | 17 | | controlled
substance, whether by injection, inhalation, | 18 | | ingestion, or any other
means, to the body of a patient, | 19 | | research subject, or animal (as
defined by the Humane | 20 | | Euthanasia in Animal Shelters Act) by:
| 21 | | (1) a practitioner (or, in his or her presence, by his | 22 | | or her authorized agent),
| 23 | | (2) the patient or research subject pursuant to an |
| | | SB1987 | - 2 - | LRB103 25792 RLC 57149 b |
|
| 1 | | order, or
| 2 | | (3) a euthanasia technician as defined by the Humane | 3 | | Euthanasia in
Animal Shelters Act.
| 4 | | (c) "Agent" means an authorized person who acts on behalf | 5 | | of or at
the direction of a manufacturer, distributor, | 6 | | dispenser, prescriber, or practitioner. It does not
include a | 7 | | common or contract carrier, public warehouseman or employee of
| 8 | | the carrier or warehouseman.
| 9 | | (c-1) "Anabolic Steroids" means any drug or hormonal | 10 | | substance,
chemically and pharmacologically related to | 11 | | testosterone (other than
estrogens, progestins, | 12 | | corticosteroids, and dehydroepiandrosterone),
and includes:
| 13 | | (i) 3[beta],17-dihydroxy-5a-androstane, | 14 | | (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, | 15 | | (iii) 5[alpha]-androstan-3,17-dione, | 16 | | (iv) 1-androstenediol (3[beta], | 17 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | 18 | | (v) 1-androstenediol (3[alpha], | 19 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | 20 | | (vi) 4-androstenediol | 21 | | (3[beta],17[beta]-dihydroxy-androst-4-ene), | 22 | | (vii) 5-androstenediol | 23 | | (3[beta],17[beta]-dihydroxy-androst-5-ene), | 24 | | (viii) 1-androstenedione | 25 | | ([5alpha]-androst-1-en-3,17-dione), | 26 | | (ix) 4-androstenedione |
| | | SB1987 | - 3 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (androst-4-en-3,17-dione), | 2 | | (x) 5-androstenedione | 3 | | (androst-5-en-3,17-dione), | 4 | | (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- | 5 | | hydroxyandrost-4-en-3-one), | 6 | | (xii) boldenone (17[beta]-hydroxyandrost- | 7 | | 1,4,-diene-3-one), | 8 | | (xiii) boldione (androsta-1,4- | 9 | | diene-3,17-dione), | 10 | | (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 | 11 | | [beta]-hydroxyandrost-4-en-3-one), | 12 | | (xv) clostebol (4-chloro-17[beta]- | 13 | | hydroxyandrost-4-en-3-one), | 14 | | (xvi) dehydrochloromethyltestosterone (4-chloro- | 15 | | 17[beta]-hydroxy-17[alpha]-methyl- | 16 | | androst-1,4-dien-3-one), | 17 | | (xvii) desoxymethyltestosterone | 18 | | (17[alpha]-methyl-5[alpha] | 19 | | -androst-2-en-17[beta]-ol)(a.k.a., madol), | 20 | | (xviii) [delta]1-dihydrotestosterone (a.k.a. | 21 | | '1-testosterone') (17[beta]-hydroxy- | 22 | | 5[alpha]-androst-1-en-3-one), | 23 | | (xix) 4-dihydrotestosterone (17[beta]-hydroxy- | 24 | | androstan-3-one), | 25 | | (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- | 26 | | 5[alpha]-androstan-3-one), |
| | | SB1987 | - 4 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- | 2 | | hydroxyestr-4-ene), | 3 | | (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- | 4 | | 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), | 5 | | (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], | 6 | | 17[beta]-dihydroxyandrost-1,4-dien-3-one), | 7 | | (xxiv) furazabol (17[alpha]-methyl-17[beta]- | 8 | | hydroxyandrostano[2,3-c]-furazan), | 9 | | (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, | 10 | | (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- | 11 | | androst-4-en-3-one), | 12 | | (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- | 13 | | dihydroxy-estr-4-en-3-one), | 14 | | (xxviii) mestanolone (17[alpha]-methyl-17[beta]- | 15 | | hydroxy-5-androstan-3-one), | 16 | | (xxix) mesterolone (1amethyl-17[beta]-hydroxy- | 17 | | [5a]-androstan-3-one), | 18 | | (xxx) methandienone (17[alpha]-methyl-17[beta]- | 19 | | hydroxyandrost-1,4-dien-3-one), | 20 | | (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- | 21 | | dihydroxyandrost-5-ene), | 22 | | (xxxii) methenolone (1-methyl-17[beta]-hydroxy- | 23 | | 5[alpha]-androst-1-en-3-one), | 24 | | (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- | 25 | | dihydroxy-5a-androstane, | 26 | | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy |
| | | SB1987 | - 5 - | LRB103 25792 RLC 57149 b |
|
| 1 | | -5a-androstane, | 2 | | (xxxv) 17[alpha]-methyl-3[beta],17[beta]- | 3 | | dihydroxyandrost-4-ene), | 4 | | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- | 5 | | methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), | 6 | | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- | 7 | | hydroxyestra-4,9(10)-dien-3-one), | 8 | | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- | 9 | | hydroxyestra-4,9-11-trien-3-one), | 10 | | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- | 11 | | hydroxyandrost-4-en-3-one), | 12 | | (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- | 13 | | hydroxyestr-4-en-3-one), | 14 | | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone | 15 | | (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- | 16 | | androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- | 17 | | 1-testosterone'), | 18 | | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), | 19 | | (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- | 20 | | dihydroxyestr-4-ene), | 21 | | (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- | 22 | | dihydroxyestr-4-ene), | 23 | | (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- | 24 | | dihydroxyestr-5-ene), | 25 | | (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- | 26 | | dihydroxyestr-5-ene), |
| | | SB1987 | - 6 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (xlvii) 19-nor-4,9(10)-androstadienedione | 2 | | (estra-4,9(10)-diene-3,17-dione), | 3 | | (xlviii) 19-nor-4-androstenedione (estr-4- | 4 | | en-3,17-dione), | 5 | | (xlix) 19-nor-5-androstenedione (estr-5- | 6 | | en-3,17-dione), | 7 | | (l) norbolethone (13[beta], 17a-diethyl-17[beta]- | 8 | | hydroxygon-4-en-3-one), | 9 | | (li) norclostebol (4-chloro-17[beta]- | 10 | | hydroxyestr-4-en-3-one), | 11 | | (lii) norethandrolone (17[alpha]-ethyl-17[beta]- | 12 | | hydroxyestr-4-en-3-one), | 13 | | (liii) normethandrolone (17[alpha]-methyl-17[beta]- | 14 | | hydroxyestr-4-en-3-one), | 15 | | (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- | 16 | | 2-oxa-5[alpha]-androstan-3-one), | 17 | | (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- | 18 | | dihydroxyandrost-4-en-3-one), | 19 | | (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- | 20 | | 17[beta]-hydroxy-(5[alpha]-androstan-3-one), | 21 | | (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- | 22 | | (5[alpha]-androst-2-eno[3,2-c]-pyrazole), | 23 | | (lviii) stenbolone (17[beta]-hydroxy-2-methyl- | 24 | | (5[alpha]-androst-1-en-3-one), | 25 | | (lix) testolactone (13-hydroxy-3-oxo-13,17- | 26 | | secoandrosta-1,4-dien-17-oic |
| | | SB1987 | - 7 - | LRB103 25792 RLC 57149 b |
|
| 1 | | acid lactone), | 2 | | (lx) testosterone (17[beta]-hydroxyandrost- | 3 | | 4-en-3-one), | 4 | | (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- | 5 | | diethyl-17[beta]-hydroxygon- | 6 | | 4,9,11-trien-3-one), | 7 | | (lxii) trenbolone (17[beta]-hydroxyestr-4,9, | 8 | | 11-trien-3-one).
| 9 | | Any person who is otherwise lawfully in possession of an | 10 | | anabolic
steroid, or who otherwise lawfully manufactures, | 11 | | distributes, dispenses,
delivers, or possesses with intent to | 12 | | deliver an anabolic steroid, which
anabolic steroid is | 13 | | expressly intended for and lawfully allowed to be
administered | 14 | | through implants to livestock or other nonhuman species, and
| 15 | | which is approved by the Secretary of Health and Human | 16 | | Services for such
administration, and which the person intends | 17 | | to administer or have
administered through such implants, | 18 | | shall not be considered to be in
unauthorized possession or to | 19 | | unlawfully manufacture, distribute, dispense,
deliver, or | 20 | | possess with intent to deliver such anabolic steroid for
| 21 | | purposes of this Act.
| 22 | | (d) "Administration" means the Drug Enforcement | 23 | | Administration,
United States Department of Justice, or its | 24 | | successor agency.
| 25 | | (d-5) "Clinical Director, Prescription Monitoring Program" | 26 | | means a Department of Human Services administrative employee |
| | | SB1987 | - 8 - | LRB103 25792 RLC 57149 b |
|
| 1 | | licensed to either prescribe or dispense controlled substances | 2 | | who shall run the clinical aspects of the Department of Human | 3 | | Services Prescription Monitoring Program and its Prescription | 4 | | Information Library. | 5 | | (d-10) "Compounding" means the preparation and mixing of | 6 | | components, excluding flavorings, (1) as the result of a | 7 | | prescriber's prescription drug order or initiative based on | 8 | | the prescriber-patient-pharmacist relationship in the course | 9 | | of professional practice or (2) for the purpose of, or | 10 | | incident to, research, teaching, or chemical analysis and not | 11 | | for sale or dispensing. "Compounding" includes the preparation | 12 | | of drugs or devices in anticipation of receiving prescription | 13 | | drug orders based on routine, regularly observed dispensing | 14 | | patterns. Commercially available products may be compounded | 15 | | for dispensing to individual patients only if both of the | 16 | | following conditions are met: (i) the commercial product is | 17 | | not reasonably available from normal distribution channels in | 18 | | a timely manner to meet the patient's needs and (ii) the | 19 | | prescribing practitioner has requested that the drug be | 20 | | compounded. | 21 | | (e) "Control" means to add a drug or other substance, or | 22 | | immediate
precursor, to a Schedule whether by
transfer from | 23 | | another Schedule or otherwise.
| 24 | | (f) "Controlled Substance" means (i) a drug, substance, | 25 | | immediate
precursor, or synthetic drug in the Schedules of | 26 | | Article II of this Act or (ii) a drug or other substance, or |
| | | SB1987 | - 9 - | LRB103 25792 RLC 57149 b |
|
| 1 | | immediate precursor, designated as a controlled substance by | 2 | | the Department through administrative rule. The term does not | 3 | | include distilled spirits, wine, malt beverages, or tobacco, | 4 | | as those terms are
defined or used in the Liquor Control Act of | 5 | | 1934 and the Tobacco Products Tax
Act of 1995.
| 6 | | (f-5) "Controlled substance analog" means a substance: | 7 | | (1) the chemical structure of which is substantially | 8 | | similar to the chemical structure of a controlled | 9 | | substance in Schedule I or II; | 10 | | (2) which has a stimulant, depressant, or | 11 | | hallucinogenic effect on the central nervous system that | 12 | | is substantially similar to or greater than the stimulant, | 13 | | depressant, or hallucinogenic effect on the central | 14 | | nervous system of a controlled substance in Schedule I or | 15 | | II; or | 16 | | (3) with respect to a particular person, which such | 17 | | person represents or intends to have a stimulant, | 18 | | depressant, or hallucinogenic effect on the central | 19 | | nervous system that is substantially similar to or greater | 20 | | than the stimulant, depressant, or hallucinogenic effect | 21 | | on the central nervous system of a controlled substance in | 22 | | Schedule I or II. | 23 | | (g) "Counterfeit substance" means a controlled substance, | 24 | | which, or
the container or labeling of which, without | 25 | | authorization bears the
trademark, trade name, or other | 26 | | identifying mark, imprint, number or
device, or any likeness |
| | | SB1987 | - 10 - | LRB103 25792 RLC 57149 b |
|
| 1 | | thereof, of a manufacturer, distributor, or
dispenser other | 2 | | than the person who in fact manufactured, distributed,
or | 3 | | dispensed the substance.
| 4 | | (h) "Deliver" or "delivery" means the actual, constructive | 5 | | or
attempted transfer of possession of a controlled substance, | 6 | | with or
without consideration, whether or not there is an | 7 | | agency relationship.
"Deliver" or "delivery" does not include
| 8 | | the donation of drugs to the extent permitted
under the | 9 | | Illinois Drug Reuse Opportunity Program Act.
| 10 | | (i) "Department" means the Illinois Department of Human | 11 | | Services (as
successor to the Department of Alcoholism and | 12 | | Substance Abuse) or its successor agency.
| 13 | | (j) (Blank).
| 14 | | (k) "Department of Corrections" means the Department of | 15 | | Corrections
of the State of Illinois or its successor agency.
| 16 | | (l) "Department of Financial and Professional Regulation" | 17 | | means the Department
of Financial and Professional Regulation | 18 | | of the State of Illinois or its successor agency.
| 19 | | (m) "Depressant" means any drug that (i) causes an overall | 20 | | depression of central nervous system functions, (ii) causes | 21 | | impaired consciousness and awareness, and (iii) can be | 22 | | habit-forming or lead to a substance abuse problem, including, | 23 | | but not limited to, alcohol, cannabis and its active | 24 | | principles and their analogs, benzodiazepines and their | 25 | | analogs, barbiturates and their analogs, opioids (natural and | 26 | | synthetic) and their analogs, and chloral hydrate and similar |
| | | SB1987 | - 11 - | LRB103 25792 RLC 57149 b |
|
| 1 | | sedative hypnotics.
| 2 | | (n) (Blank).
| 3 | | (o) "Director" means the Director of the Illinois State | 4 | | Police or his or her designated agents.
| 5 | | (p) "Dispense" means to deliver a controlled substance to | 6 | | an
ultimate user or research subject by or pursuant to the | 7 | | lawful order of
a prescriber, including the prescribing, | 8 | | administering, packaging,
labeling, or compounding necessary | 9 | | to prepare the substance for that
delivery.
| 10 | | (q) "Dispenser" means a practitioner who dispenses.
| 11 | | (r) "Distribute" means to deliver, other than by | 12 | | administering or
dispensing, a controlled substance.
| 13 | | (s) "Distributor" means a person who distributes.
| 14 | | (t) "Drug" means (1) substances recognized as drugs in the | 15 | | official
United States Pharmacopoeia, Official Homeopathic | 16 | | Pharmacopoeia of the
United States, or official National | 17 | | Formulary, or any supplement to any
of them; (2) substances | 18 | | intended for use in diagnosis, cure, mitigation,
treatment, or | 19 | | prevention of disease in man or animals; (3) substances
(other | 20 | | than food) intended to affect the structure of any function of
| 21 | | the body of man or animals and (4) substances intended for use | 22 | | as a
component of any article specified in clause (1), (2), or | 23 | | (3) of this
subsection. It does not include devices or their | 24 | | components, parts, or
accessories.
| 25 | | (t-3) "Electronic health record" or "EHR" means an | 26 | | electronic record of health-related information on an |
| | | SB1987 | - 12 - | LRB103 25792 RLC 57149 b |
|
| 1 | | individual that is created, gathered, managed, and consulted | 2 | | by authorized health care clinicians and staff. | 3 | | (t-3.5) "Electronic health record system" or "EHR system" | 4 | | means any computer-based system or combination of federally | 5 | | certified Health IT Modules (defined at 42 CFR 170.102 or its | 6 | | successor) used as a repository for electronic health records | 7 | | and accessed or updated by a prescriber or authorized | 8 | | surrogate in the ordinary course of his or her medical | 9 | | practice. For purposes of connecting to the Prescription | 10 | | Information Library maintained by the Bureau of Pharmacy and | 11 | | Clinical Support Systems or its successor, an EHR system may | 12 | | connect to the Prescription Information Library directly or | 13 | | through all or part of a computer program or system that is a | 14 | | federally certified Health IT Module maintained by a third | 15 | | party and used by the EHR system to secure access to the | 16 | | database. | 17 | | (t-4) "Emergency medical services personnel" has the | 18 | | meaning ascribed to it in the Emergency Medical Services (EMS) | 19 | | Systems Act. | 20 | | (t-5) "Euthanasia agency" means
an entity certified by the | 21 | | Department of Financial and Professional Regulation for the
| 22 | | purpose of animal euthanasia that holds an animal control | 23 | | facility license or
animal
shelter license under the Animal | 24 | | Welfare Act. A euthanasia agency is
authorized to purchase, | 25 | | store, possess, and utilize Schedule II nonnarcotic and
| 26 | | Schedule III nonnarcotic drugs for the sole purpose of animal |
| | | SB1987 | - 13 - | LRB103 25792 RLC 57149 b |
|
| 1 | | euthanasia.
| 2 | | (t-10) "Euthanasia drugs" means Schedule II or Schedule | 3 | | III substances
(nonnarcotic controlled substances) that are | 4 | | used by a euthanasia agency for
the purpose of animal | 5 | | euthanasia.
| 6 | | (u) "Good faith" means the prescribing or dispensing of a | 7 | | controlled
substance by a practitioner in the regular course | 8 | | of professional
treatment to or for any person who is under his | 9 | | or her treatment for a
pathology or condition other than that | 10 | | individual's physical or
psychological dependence upon or | 11 | | addiction to a controlled substance,
except as provided | 12 | | herein: and application of the term to a pharmacist
shall mean | 13 | | the dispensing of a controlled substance pursuant to the
| 14 | | prescriber's order which in the professional judgment of the | 15 | | pharmacist
is lawful. The pharmacist shall be guided by | 16 | | accepted professional
standards, including, but not limited | 17 | | to, the following, in making the
judgment:
| 18 | | (1) lack of consistency of prescriber-patient | 19 | | relationship,
| 20 | | (2) frequency of prescriptions for same drug by one | 21 | | prescriber for
large numbers of patients,
| 22 | | (3) quantities beyond those normally prescribed,
| 23 | | (4) unusual dosages (recognizing that there may be | 24 | | clinical circumstances where more or less than the usual | 25 | | dose may be used legitimately),
| 26 | | (5) unusual geographic distances between patient, |
| | | SB1987 | - 14 - | LRB103 25792 RLC 57149 b |
|
| 1 | | pharmacist and
prescriber,
| 2 | | (6) consistent prescribing of habit-forming drugs.
| 3 | | (u-0.5) "Hallucinogen" means a drug that causes markedly | 4 | | altered sensory perception leading to hallucinations of any | 5 | | type. | 6 | | (u-1) "Home infusion services" means services provided by | 7 | | a pharmacy in
compounding solutions for direct administration | 8 | | to a patient in a private
residence, long-term care facility, | 9 | | or hospice setting by means of parenteral,
intravenous, | 10 | | intramuscular, subcutaneous, or intraspinal infusion.
| 11 | | (u-5) "Illinois State Police" means the Illinois State
| 12 | | Police or its successor agency. | 13 | | (v) "Immediate precursor" means a substance:
| 14 | | (1) which the Department has found to be and by rule | 15 | | designated as
being a principal compound used, or produced | 16 | | primarily for use, in the
manufacture of a controlled | 17 | | substance;
| 18 | | (2) which is an immediate chemical intermediary used | 19 | | or likely to
be used in the manufacture of such controlled | 20 | | substance; and
| 21 | | (3) the control of which is necessary to prevent, | 22 | | curtail or limit
the manufacture of such controlled | 23 | | substance.
| 24 | | (w) "Instructional activities" means the acts of teaching, | 25 | | educating
or instructing by practitioners using controlled | 26 | | substances within
educational facilities approved by the State |
| | | SB1987 | - 15 - | LRB103 25792 RLC 57149 b |
|
| 1 | | Board of Education or
its successor agency.
| 2 | | (w-1) "Isomer" means optical isomer unless specifically | 3 | | described in this Act. | 4 | | (x) "Local authorities" means a duly organized State, | 5 | | County or
Municipal peace unit or police force.
| 6 | | (y) "Look-alike substance" means a substance, other than a | 7 | | controlled
substance which (1) by overall dosage unit | 8 | | appearance, including shape,
color, size, markings or lack | 9 | | thereof, taste, consistency, or any other
identifying physical | 10 | | characteristic of the substance, would lead a reasonable
| 11 | | person to believe that the substance is a controlled | 12 | | substance, or (2) is
expressly or impliedly represented to be | 13 | | a controlled substance or is
distributed under circumstances | 14 | | which would lead a reasonable person to
believe that the | 15 | | substance is a controlled substance. For the purpose of
| 16 | | determining whether the representations made or the | 17 | | circumstances of the
distribution would lead a reasonable | 18 | | person to believe the substance to be
a controlled substance | 19 | | under this clause (2) of subsection (y), the court or
other | 20 | | authority may consider the following factors in addition to | 21 | | any other
factor that may be relevant:
| 22 | | (a) statements made by the owner or person in control | 23 | | of the substance
concerning its nature, use or effect;
| 24 | | (b) statements made to the buyer or recipient that the | 25 | | substance may
be resold for profit;
| 26 | | (c) whether the substance is packaged in a manner |
| | | SB1987 | - 16 - | LRB103 25792 RLC 57149 b |
|
| 1 | | normally used for the
illegal distribution of controlled | 2 | | substances;
| 3 | | (d) whether the distribution or attempted distribution | 4 | | included an
exchange of or demand for money or other | 5 | | property as consideration, and
whether the amount of the | 6 | | consideration was substantially greater than the
| 7 | | reasonable retail market value of the substance.
| 8 | | Clause (1) of this subsection (y) shall not apply to a | 9 | | noncontrolled
substance in its finished dosage form that was | 10 | | initially introduced into
commerce prior to the initial | 11 | | introduction into commerce of a controlled
substance in its | 12 | | finished dosage form which it may substantially resemble.
| 13 | | Nothing in this subsection (y) prohibits the dispensing or | 14 | | distributing
of noncontrolled substances by persons authorized | 15 | | to dispense and
distribute controlled substances under this | 16 | | Act, provided that such action
would be deemed to be carried | 17 | | out in good faith under subsection (u) if the
substances | 18 | | involved were controlled substances.
| 19 | | Nothing in this subsection (y) or in this Act prohibits | 20 | | the manufacture,
preparation, propagation, compounding, | 21 | | processing, packaging, advertising
or distribution of a drug | 22 | | or drugs by any person registered pursuant to
Section 510 of | 23 | | the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
| 24 | | (y-1) "Mail-order pharmacy" means a pharmacy that is | 25 | | located in a state
of the United States that delivers, | 26 | | dispenses or
distributes, through the United States Postal |
| | | SB1987 | - 17 - | LRB103 25792 RLC 57149 b |
|
| 1 | | Service or other common
carrier, to Illinois residents, any | 2 | | substance which requires a prescription.
| 3 | | (z) "Manufacture" means the production, preparation, | 4 | | propagation,
compounding, conversion or processing of a | 5 | | controlled substance other than methamphetamine, either
| 6 | | directly or indirectly, by extraction from substances of | 7 | | natural origin,
or independently by means of chemical | 8 | | synthesis, or by a combination of
extraction and chemical | 9 | | synthesis, and includes any packaging or
repackaging of the | 10 | | substance or labeling of its container, except that
this term | 11 | | does not include:
| 12 | | (1) by an ultimate user, the preparation or | 13 | | compounding of a
controlled substance for his or her own | 14 | | use;
| 15 | | (2) by a practitioner, or his or her authorized agent | 16 | | under his or her
supervision, the preparation, | 17 | | compounding, packaging, or labeling of a
controlled | 18 | | substance:
| 19 | | (a) as an incident to his or her administering or | 20 | | dispensing of a
controlled substance in the course of | 21 | | his or her professional practice; or
| 22 | | (b) as an incident to lawful research, teaching or | 23 | | chemical
analysis and not for sale; or
| 24 | | (3) the packaging, repackaging, or labeling of
drugs | 25 | | only to the extent permitted under the
Illinois Drug Reuse | 26 | | Opportunity Program Act.
|
| | | SB1987 | - 18 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (z-1) (Blank).
| 2 | | (z-5) "Medication shopping" means the conduct prohibited | 3 | | under subsection (a) of Section 314.5 of this Act. | 4 | | (z-10) "Mid-level practitioner" means (i) a physician | 5 | | assistant who has been delegated authority to prescribe | 6 | | through a written delegation of authority by a physician | 7 | | licensed to practice medicine in all of its branches, in | 8 | | accordance with Section 7.5 of the Physician Assistant | 9 | | Practice Act of 1987, (ii) an advanced practice registered | 10 | | nurse who has been delegated authority to prescribe through a | 11 | | written delegation of authority by a physician licensed to | 12 | | practice medicine in all of its branches or by a podiatric | 13 | | physician, in accordance with Section 65-40 of the Nurse | 14 | | Practice Act, (iii) an advanced practice registered nurse | 15 | | certified as a nurse practitioner, nurse midwife, or clinical | 16 | | nurse specialist who has been granted authority to prescribe | 17 | | by a hospital affiliate in accordance with Section 65-45 of | 18 | | the Nurse Practice Act, (iv) an animal euthanasia agency, or | 19 | | (v) a prescribing psychologist. | 20 | | (aa) "Narcotic drug" means any of the following, whether | 21 | | produced
directly or indirectly by extraction from substances | 22 | | of vegetable origin,
or independently by means of chemical | 23 | | synthesis, or by a combination of
extraction and chemical | 24 | | synthesis:
| 25 | | (1) opium, opiates, derivatives of opium and opiates, | 26 | | including their isomers, esters, ethers, salts, and salts |
| | | SB1987 | - 19 - | LRB103 25792 RLC 57149 b |
|
| 1 | | of isomers, esters, and ethers, whenever the existence of | 2 | | such isomers, esters, ethers, and salts is possible within | 3 | | the specific chemical designation; however the term | 4 | | "narcotic drug" does not include the isoquinoline | 5 | | alkaloids of opium;
| 6 | | (2) (blank);
| 7 | | (3) opium poppy and poppy straw;
| 8 | | (4) coca leaves, except coca leaves and extracts of | 9 | | coca leaves from which substantially all of the cocaine | 10 | | and ecgonine, and their isomers, derivatives and salts, | 11 | | have been removed;
| 12 | | (5) cocaine, its salts, optical and geometric isomers, | 13 | | and salts of isomers; | 14 | | (6) ecgonine, its derivatives, their salts, isomers, | 15 | | and salts of isomers; | 16 | | (7) any compound, mixture, or preparation which | 17 | | contains any quantity of any of the substances referred to | 18 | | in subparagraphs (1) through (6). | 19 | | (bb) "Nurse" means a registered nurse licensed under the
| 20 | | Nurse Practice Act.
| 21 | | (cc) (Blank).
| 22 | | (dd) "Opiate" means any substance having an addiction | 23 | | forming or
addiction sustaining liability similar to morphine | 24 | | or being capable of
conversion into a drug having addiction | 25 | | forming or addiction sustaining
liability.
| 26 | | (ee) "Opium poppy" means the plant of the species Papaver
|
| | | SB1987 | - 20 - | LRB103 25792 RLC 57149 b |
|
| 1 | | somniferum L., except its seeds.
| 2 | | (ee-5) "Oral dosage" means a tablet, capsule, elixir, or | 3 | | solution or other liquid form of medication intended for | 4 | | administration by mouth, but the term does not include a form | 5 | | of medication intended for buccal, sublingual, or transmucosal | 6 | | administration. | 7 | | (ff) "Parole and Pardon Board" means the Parole and Pardon | 8 | | Board of
the State of Illinois or its successor agency.
| 9 | | (gg) "Person" means any individual, corporation, | 10 | | mail-order pharmacy,
government or governmental subdivision or | 11 | | agency, business trust, estate,
trust, partnership or | 12 | | association, or any other entity.
| 13 | | (hh) "Pharmacist" means any person who holds a license or | 14 | | certificate of
registration as a registered pharmacist, a | 15 | | local registered pharmacist
or a registered assistant | 16 | | pharmacist under the Pharmacy Practice Act.
| 17 | | (ii) "Pharmacy" means any store, ship or other place in | 18 | | which
pharmacy is authorized to be practiced under the | 19 | | Pharmacy Practice Act.
| 20 | | (ii-5) "Pharmacy shopping" means the conduct prohibited | 21 | | under subsection (b) of Section 314.5 of this Act. | 22 | | (ii-10) "Physician" (except when the context otherwise | 23 | | requires) means a person licensed to practice medicine in all | 24 | | of its branches. | 25 | | (jj) "Poppy straw" means all parts, except the seeds, of | 26 | | the opium
poppy, after mowing.
|
| | | SB1987 | - 21 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (kk) "Practitioner" means a physician licensed to practice | 2 | | medicine in all
its branches, dentist, optometrist, podiatric | 3 | | physician,
veterinarian, scientific investigator, pharmacist, | 4 | | physician assistant,
advanced practice registered nurse,
| 5 | | licensed practical
nurse, registered nurse, emergency medical | 6 | | services personnel, hospital, laboratory, or pharmacy, or | 7 | | other
person licensed, registered, or otherwise lawfully | 8 | | permitted by the
United States or this State to distribute, | 9 | | dispense, conduct research
with respect to, administer or use | 10 | | in teaching or chemical analysis, a
controlled substance in | 11 | | the course of professional practice or research.
| 12 | | (ll) "Pre-printed prescription" means a written | 13 | | prescription upon which
the designated drug has been indicated | 14 | | prior to the time of issuance; the term does not mean a written | 15 | | prescription that is individually generated by machine or | 16 | | computer in the prescriber's office.
| 17 | | (mm) "Prescriber" means a physician licensed to practice | 18 | | medicine in all
its branches, dentist, optometrist, | 19 | | prescribing psychologist licensed under Section 4.2 of the | 20 | | Clinical Psychologist Licensing Act with prescriptive | 21 | | authority delegated under Section 4.3 of the Clinical | 22 | | Psychologist Licensing Act, podiatric physician, or
| 23 | | veterinarian who issues a prescription, a physician assistant | 24 | | who
issues a
prescription for a controlled substance
in | 25 | | accordance
with Section 303.05, a written delegation, and a | 26 | | written collaborative agreement required under Section 7.5
of |
| | | SB1987 | - 22 - | LRB103 25792 RLC 57149 b |
|
| 1 | | the
Physician Assistant Practice Act of 1987, an advanced | 2 | | practice registered
nurse with prescriptive authority | 3 | | delegated under Section 65-40 of the Nurse Practice Act and in | 4 | | accordance with Section 303.05, a written delegation,
and a | 5 | | written
collaborative agreement under Section 65-35 of the | 6 | | Nurse Practice Act, an advanced practice registered nurse | 7 | | certified as a nurse practitioner, nurse midwife, or clinical | 8 | | nurse specialist who has been granted authority to prescribe | 9 | | by a hospital affiliate in accordance with Section 65-45 of | 10 | | the Nurse Practice Act and in accordance with Section 303.05, | 11 | | or an advanced practice registered nurse certified as a nurse | 12 | | practitioner, nurse midwife, or clinical nurse specialist who | 13 | | has full practice authority pursuant to Section 65-43 of the | 14 | | Nurse Practice Act.
| 15 | | (nn) "Prescription" means a written, facsimile, or oral | 16 | | order, or an electronic order that complies with applicable | 17 | | federal requirements,
of
a physician licensed to practice | 18 | | medicine in all its branches,
dentist, podiatric physician or | 19 | | veterinarian for any controlled
substance, of an optometrist | 20 | | in accordance with Section 15.1 of the Illinois Optometric | 21 | | Practice Act of 1987, of a prescribing psychologist licensed | 22 | | under Section 4.2 of the Clinical Psychologist Licensing Act | 23 | | with prescriptive authority delegated under Section 4.3 of the | 24 | | Clinical Psychologist Licensing Act, of a physician assistant | 25 | | for a
controlled substance
in accordance with Section 303.05, | 26 | | a written delegation, and a written collaborative agreement |
| | | SB1987 | - 23 - | LRB103 25792 RLC 57149 b |
|
| 1 | | required under
Section 7.5 of the
Physician Assistant Practice | 2 | | Act of 1987, of an advanced practice registered
nurse with | 3 | | prescriptive authority delegated under Section 65-40 of the | 4 | | Nurse Practice Act who issues a prescription for a
controlled | 5 | | substance in accordance
with
Section 303.05, a written | 6 | | delegation, and a written collaborative agreement under | 7 | | Section 65-35 of the Nurse Practice Act, of an advanced | 8 | | practice registered nurse certified as a nurse practitioner, | 9 | | nurse midwife, or clinical nurse specialist who has been | 10 | | granted authority to prescribe by a hospital affiliate in | 11 | | accordance with Section 65-45 of the Nurse Practice Act and in | 12 | | accordance with Section 303.05 when required by law, or of an | 13 | | advanced practice registered nurse certified as a nurse | 14 | | practitioner, nurse midwife, or clinical nurse specialist who | 15 | | has full practice authority pursuant to Section 65-43 of the | 16 | | Nurse Practice Act.
| 17 | | (nn-5) "Prescription Information Library" (PIL) means an | 18 | | electronic library that contains reported controlled substance | 19 | | data. | 20 | | (nn-10) "Prescription Monitoring Program" (PMP) means the | 21 | | entity that collects, tracks, and stores reported data on | 22 | | controlled substances and select drugs pursuant to Section | 23 | | 316. | 24 | | (oo) "Production" or "produce" means manufacture, | 25 | | planting,
cultivating, growing, or harvesting of a controlled | 26 | | substance other than methamphetamine.
|
| | | SB1987 | - 24 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (pp) "Registrant" means every person who is required to | 2 | | register
under Section 302 of this Act.
| 3 | | (qq) "Registry number" means the number assigned to each | 4 | | person
authorized to handle controlled substances under the | 5 | | laws of the United
States and of this State.
| 6 | | (qq-5) "Secretary" means, as the context requires, either | 7 | | the Secretary of the Department or the Secretary of the | 8 | | Department of Financial and Professional Regulation, and the | 9 | | Secretary's designated agents. | 10 | | (rr) "State" includes the State of Illinois and any state, | 11 | | district,
commonwealth, territory, insular possession thereof, | 12 | | and any area
subject to the legal authority of the United | 13 | | States of America.
| 14 | | (rr-5) "Stimulant" means any drug that (i) causes an | 15 | | overall excitation of central nervous system functions, (ii) | 16 | | causes impaired consciousness and awareness, and (iii) can be | 17 | | habit-forming or lead to a substance abuse problem, including, | 18 | | but not limited to, amphetamines and their analogs, | 19 | | methylphenidate and its analogs, cocaine, and phencyclidine | 20 | | and its analogs. | 21 | | (rr-10) "Synthetic drug" includes, but is not limited to, | 22 | | any synthetic cannabinoids or piperazines or any synthetic | 23 | | cathinones as provided for in Schedule I. | 24 | | (ss) "Ultimate user" means a person who lawfully possesses | 25 | | a
controlled substance for his or her own use or for the use of | 26 | | a member of his or her
household or for administering to an |
| | | SB1987 | - 25 - | LRB103 25792 RLC 57149 b |
|
| 1 | | animal owned by him or her or by a member
of his or her | 2 | | household.
| 3 | | (Source: P.A. 101-666, eff. 1-1-22; 102-389, eff. 1-1-22; | 4 | | 102-538, eff. 8-20-21; 102-813, eff. 5-13-22.)
| 5 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | 6 | | Sec. 204. (a) The controlled substances listed in this | 7 | | Section are
included in Schedule I. | 8 | | (b) Unless specifically excepted or unless listed in | 9 | | another
schedule, any of the following opiates, including | 10 | | their isomers,
esters, ethers, salts, and salts of isomers, | 11 | | esters, and ethers,
whenever the existence of such isomers, | 12 | | esters, ethers and salts is
possible within the specific | 13 | | chemical designation: | 14 | | (1) Acetylmethadol; | 15 | | (1.1) Acetyl-alpha-methylfentanyl | 16 | | (N-[1-(1-methyl-2-phenethyl)-
| 17 | | 4-piperidinyl]-N-phenylacetamide); | 18 | | (2) Allylprodine; | 19 | | (3) Alphacetylmethadol, except
| 20 | | levo-alphacetylmethadol (also known as levo-alpha-
| 21 | | acetylmethadol, levomethadyl acetate, or LAAM); | 22 | | (4) Alphameprodine; | 23 | | (5) Alphamethadol; | 24 | | (6) Alpha-methylfentanyl
| 25 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
|
| | | SB1987 | - 26 - | LRB103 25792 RLC 57149 b |
|
| 1 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| 2 | | propanilido) piperidine; | 3 | | (6.1) Alpha-methylthiofentanyl
| 4 | | (N-[1-methyl-2-(2-thienyl)ethyl-
| 5 | | 4-piperidinyl]-N-phenylpropanamide); | 6 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | 7 | | (7.1) PEPAP
| 8 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | 9 | | (8) Benzethidine; | 10 | | (9) Betacetylmethadol; | 11 | | (9.1) Beta-hydroxyfentanyl
| 12 | | (N-[1-(2-hydroxy-2-phenethyl)-
| 13 | | 4-piperidinyl]-N-phenylpropanamide); | 14 | | (10) Betameprodine; | 15 | | (11) Betamethadol; | 16 | | (12) Betaprodine; | 17 | | (12.1) Brorphine; | 18 | | (13) Clonitazene; | 19 | | (14) Dextromoramide; | 20 | | (15) Diampromide; | 21 | | (16) Diethylthiambutene; | 22 | | (17) Difenoxin; | 23 | | (18) Dimenoxadol; | 24 | | (19) Dimepheptanol; | 25 | | (20) Dimethylthiambutene; | 26 | | (21) Dioxaphetylbutyrate; |
| | | SB1987 | - 27 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (22) Dipipanone; | 2 | | (23) Ethylmethylthiambutene; | 3 | | (24) Etonitazene; | 4 | | (25) Etoxeridine; | 5 | | (25.1) Flunitazene; | 6 | | | 7 | | (26) Furethidine; | 8 | | (27) Hydroxpethidine; | 9 | | (27.1) Isotonitazene; | 10 | | (28) Ketobemidone; | 11 | | (29) Levomoramide; | 12 | | (30) Levophenacylmorphan; | 13 | | (31) 3-Methylfentanyl
| 14 | | (N-[3-methyl-1-(2-phenylethyl)-
| 15 | | 4-piperidyl]-N-phenylpropanamide); | 16 | | (31.1) 3-Methylthiofentanyl
| 17 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
| 18 | | 4-piperidinyl]-N-phenylpropanamide); | 19 | | (31.2) Metonitazene; | 20 | | (32) Morpheridine; | 21 | | (33) Noracymethadol; | 22 | | (34) Norlevorphanol; | 23 | | (35) Normethadone; | 24 | | (36) Norpipanone; | 25 | | (36.1) Para-fluorofentanyl
| 26 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
|
| | | SB1987 | - 28 - | LRB103 25792 RLC 57149 b |
|
| 1 | | 4-piperidinyl]propanamide); | 2 | | (37) Phenadoxone; | 3 | | (38) Phenampromide; | 4 | | (39) Phenomorphan; | 5 | | (40) Phenoperidine; | 6 | | (41) Piritramide; | 7 | | (42) Proheptazine; | 8 | | (43) Properidine; | 9 | | (44) Propiram; | 10 | | (45) Racemoramide; | 11 | | (45.1) Thiofentanyl
| 12 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
| 13 | | 4-piperidinyl]-propanamide); | 14 | | (46) Tilidine; | 15 | | (47) Trimeperidine; | 16 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
| 17 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 18 | | N-phenylpropanamide); | 19 | | (49) Furanyl fentanyl (FU-F); | 20 | | (50) Butyryl fentanyl; | 21 | | (51) Valeryl fentanyl; | 22 | | (52) Acetyl fentanyl; | 23 | | (53) Beta-hydroxy-thiofentanyl; | 24 | | (54) 3,4-dichloro-N-[2-
| 25 | | (dimethylamino)cyclohexyl]-N-
| 26 | | methylbenzamide (U-47700); |
| | | SB1987 | - 29 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (55) 4-chloro-N-[1-[2-
| 2 | | (4-nitrophenyl)ethyl]-2-piperidinylidene]-
| 3 | | benzenesulfonamide (W-18); | 4 | | (56) 4-chloro-N-[1-(2-phenylethyl)
| 5 | | -2-piperidinylidene]-benzenesulfonamide (W-15); | 6 | | (57) acrylfentanyl (acryloylfentanyl). | 7 | | (c) Unless specifically excepted or unless listed in | 8 | | another
schedule, any of the following opium derivatives, its | 9 | | salts, isomers
and salts of isomers, whenever the existence of | 10 | | such salts, isomers and
salts of isomers is possible within | 11 | | the specific chemical designation: | 12 | | (1) Acetorphine; | 13 | | (2) Acetyldihydrocodeine; | 14 | | (3) Benzylmorphine; | 15 | | (4) Codeine methylbromide; | 16 | | (5) Codeine-N-Oxide; | 17 | | (6) Cyprenorphine; | 18 | | (7) Desomorphine; | 19 | | (8) Diacetyldihydromorphine (Dihydroheroin); | 20 | | (9) Dihydromorphine; | 21 | | (10) Drotebanol; | 22 | | (11) Etorphine (except hydrochloride salt); | 23 | | (12) Heroin; | 24 | | (13) Hydromorphinol; | 25 | | (14) Methyldesorphine; | 26 | | (15) Methyldihydromorphine; |
| | | SB1987 | - 30 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (16) Morphine methylbromide; | 2 | | (17) Morphine methylsulfonate; | 3 | | (18) Morphine-N-Oxide; | 4 | | (19) Myrophine; | 5 | | (20) Nicocodeine; | 6 | | (21) Nicomorphine; | 7 | | (22) Normorphine; | 8 | | (23) Pholcodine; | 9 | | (24) Thebacon. | 10 | | (d) Unless specifically excepted or unless listed in | 11 | | another
schedule, any material, compound, mixture, or | 12 | | preparation which contains
any quantity of the following | 13 | | hallucinogenic substances, or which
contains any of its salts, | 14 | | isomers and salts of isomers, whenever the
existence of such | 15 | | salts, isomers, and salts of isomers is possible
within the | 16 | | specific chemical designation (for the purposes of this
| 17 | | paragraph only, the term "isomer" includes the optical, | 18 | | position and
geometric isomers): | 19 | | (1) 3,4-methylenedioxyamphetamine
| 20 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| 21 | | methylenedioxyamphetamine, MDA); | 22 | | (1.1) Alpha-ethyltryptamine
| 23 | | (some trade or other names: etryptamine;
| 24 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 25 | | 3-(2-aminobutyl)indole; a-ET; and AET); | 26 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); |
| | | SB1987 | - 31 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| 2 | | (also known as: N-ethyl-alpha-methyl-
| 3 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| 4 | | and MDEA); | 5 | | (2.2) (Blank); N-Benzylpiperazine (BZP); | 6 | | (2.2-1) (Blank); Trifluoromethylphenylpiperazine | 7 | | (TFMPP); | 8 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | 9 | | (4) 3,4,5-trimethoxyamphetamine (TMA); | 10 | | (5) (Blank); | 11 | | (6) Diethyltryptamine (DET); | 12 | | (7) Dimethyltryptamine (DMT); | 13 | | (7.1) 5-Methoxy-diallyltryptamine; | 14 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | 15 | | (9) Ibogaine (some trade and other names:
| 16 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 17 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| 18 | | indole; Tabernanthe iboga); | 19 | | (10) Lysergic acid diethylamide; | 20 | | (10.1) Salvinorin A; | 21 | | (10.5) Salvia divinorum (meaning all parts of the | 22 | | plant presently classified
botanically as Salvia | 23 | | divinorum, whether growing or not, the
seeds thereof, any | 24 | | extract from any part of that plant, and every compound,
| 25 | | manufacture, salts, isomers, and salts of
isomers whenever | 26 | | the existence of such salts, isomers, and salts of
isomers |
| | | SB1987 | - 32 - | LRB103 25792 RLC 57149 b |
|
| 1 | | is possible within the specific chemical designation, | 2 | | derivative, mixture, or preparation of that plant, its
| 3 | | seeds or extracts);
| 4 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | 5 | | (12) Peyote (meaning all parts of the plant presently | 6 | | classified
botanically as Lophophora williamsii
Lemaire, | 7 | | whether growing or not, the
seeds thereof, any extract | 8 | | from any part of that plant, and every compound,
| 9 | | manufacture, salts, derivative, mixture, or preparation of | 10 | | that plant, its
seeds or extracts); | 11 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); | 12 | | (14) N-methyl-3-piperidyl benzilate; | 13 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| 14 | | (also known as N-hydroxy-alpha-methyl-
| 15 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | 16 | | (15) Parahexyl; some trade or other names:
| 17 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| 18 | | dibenzo (b,d) pyran; Synhexyl; | 19 | | (16) Psilocybin; | 20 | | (17) Psilocyn; | 21 | | (18) Alpha-methyltryptamine (AMT); | 22 | | (19) 2,5-dimethoxyamphetamine
| 23 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 24 | | (20) 4-bromo-2,5-dimethoxyamphetamine
| 25 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 26 | | 4-bromo-2,5-DMA); |
| | | SB1987 | - 33 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| 2 | | Some trade or other names: 2-(4-bromo-
| 3 | | 2,5-dimethoxyphenyl)-1-aminoethane;
| 4 | | alpha-desmethyl DOB, 2CB, Nexus; | 5 | | (21) 4-methoxyamphetamine
| 6 | | (4-methoxy-alpha-methylphenethylamine;
| 7 | | paramethoxyamphetamine; PMA); | 8 | | (22) (Blank); | 9 | | (23) Ethylamine analog of phencyclidine.
| 10 | | Some trade or other names:
| 11 | | N-ethyl-1-phenylcyclohexylamine,
| 12 | | (1-phenylcyclohexyl) ethylamine,
| 13 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | 14 | | (24) Pyrrolidine analog of phencyclidine. Some trade | 15 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | 16 | | PHP; | 17 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | 18 | | (26) 2,5-dimethoxy-4-ethylamphetamine
| 19 | | (another name: DOET); | 20 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| 21 | | (another name: TCPy); | 22 | | (28) (Blank); | 23 | | (29) Thiophene analog of phencyclidine (some trade
| 24 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 25 | | 2-thienyl analog of phencyclidine; TPCP; TCP); | 26 | | (29.1) Benzothiophene analog of phencyclidine. Some |
| | | SB1987 | - 34 - | LRB103 25792 RLC 57149 b |
|
| 1 | | trade or other names: BTCP or benocyclidine; | 2 | | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); | 3 | | (30) Bufotenine (some trade or other names:
| 4 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 5 | | 3-(2-dimethylaminoethyl)-5-indolol;
| 6 | | 5-hydroxy-N,N-dimethyltryptamine;
| 7 | | N,N-dimethylserotonin; mappine); | 8 | | (31) (Blank); | 9 | | (32) (Blank); | 10 | | (33) (Blank); | 11 | | (34) (Blank); | 12 | | (34.5) (Blank); | 13 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | 14 | | (2-methyloctan-2-yl)-6a,7, | 15 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol | 16 | | Some trade or other names: HU-210; | 17 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | 18 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | 19 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, | 20 | | salts, and salts of isomers; Some trade or other | 21 | | names: HU-210, Dexanabinol; | 22 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 23 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 24 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | 25 | | Some trade or other names: HU-211; | 26 | | (37) (Blank); |
| | | SB1987 | - 35 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (38) (Blank); | 2 | | (39) (Blank); | 3 | | (40) (Blank); | 4 | | (41) (Blank); | 5 | | (42) (Blank); Any compound structurally derived from | 6 | | 3-(1-naphthoyl)indole or | 7 | | 1H-indol-3-yl-(1-naphthyl)methane by substitution at the | 8 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 9 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 10 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 11 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 12 | | in the indole ring to any extent, whether or not | 13 | | substituted in the naphthyl ring to any extent. Examples | 14 | | of this structural class include, but are not limited to, | 15 | | JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | 16 | | (43) (Blank); Any compound structurally derived from | 17 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | 18 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | 19 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 20 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 21 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 22 | | in the pyrrole ring to any extent, whether or not | 23 | | substituted in the naphthyl ring to any extent. Examples | 24 | | of this structural class include, but are not limited to, | 25 | | JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | 26 | | (44) (Blank); Any compound structurally derived from |
| | | SB1987 | - 36 - | LRB103 25792 RLC 57149 b |
|
| 1 | | 1-(1-naphthylmethyl)indene by substitution at the | 2 | | 3-position of the indene ring by alkyl, haloalkyl, | 3 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 4 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 5 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 6 | | in the indene ring to any extent, whether or not | 7 | | substituted in the naphthyl ring to any extent. Examples | 8 | | of this structural class include, but are not limited to, | 9 | | JWH-176; | 10 | | (45) (Blank); Any compound structurally derived from | 11 | | 3-phenylacetylindole by substitution at the nitrogen atom | 12 | | of the indole ring with alkyl, haloalkyl, alkenyl, | 13 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 14 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 15 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 16 | | in the indole ring to any extent, whether or not | 17 | | substituted in the phenyl ring to any extent. Examples of | 18 | | this structural class include, but are not limited to, | 19 | | JWH-167, JWH-250, JWH-251, and RCS-8; | 20 | | (46) (Blank); Any compound structurally derived from | 21 | | 2-(3-hydroxycyclohexyl)phenol by substitution at the | 22 | | 5-position of the phenolic ring by alkyl, haloalkyl, | 23 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 24 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 25 | | 2-(4-morpholinyl)ethyl, whether or not substituted in the | 26 | | cyclohexyl ring to any extent. Examples of this structural |
| | | SB1987 | - 37 - | LRB103 25792 RLC 57149 b |
|
| 1 | | class include, but are not limited to, CP 47, 497 and its | 2 | | C8 homologue (cannabicyclohexanol); | 3 | | (46.1) (Blank); Any compound structurally derived from | 4 | | 3-(benzoyl) indole with substitution at the nitrogen atom | 5 | | of the indole ring by an alkyl, haloalkyl, alkenyl, | 6 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 7 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl group whether or not further | 9 | | substituted in the indole ring to any extent and whether | 10 | | or not substituted in the phenyl ring to any extent. | 11 | | Examples of this structural class include, but are not | 12 | | limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN | 13 | | 48,098), and RCS-4; | 14 | | (47) (Blank); | 15 | | (48) (Blank); | 16 | | (49) (Blank); | 17 | | (50) (Blank); | 18 | | (51) (Blank); | 19 | | (52) (Blank); | 20 | | (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. | 21 | | Some trade or other names: 2C-T-7; | 22 | | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some | 23 | | trade or other names: 2C-E; | 24 | | (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some | 25 | | trade or other names: 2C-D; | 26 | | (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some |
| | | SB1987 | - 38 - | LRB103 25792 RLC 57149 b |
|
| 1 | | trade or other names: 2C-C; | 2 | | (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade | 3 | | or other names: 2C-I; | 4 | | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some | 5 | | trade or other names: 2C-T-2; | 6 | | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. | 7 | | Some trade or other names: 2C-T-4; | 8 | | (53.7) 2,5-dimethoxyphenethylamine. Some trade or | 9 | | other names: 2C-H; | 10 | | (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some | 11 | | trade or other names: 2C-N; | 12 | | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some | 13 | | trade or other names: 2C-P; | 14 | | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. | 15 | | Some trade or other names: 2C-G; | 16 | | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | 17 | | phenethylamine referred to in subparagraphs (20.1), (53), | 18 | | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | 19 | | (53.8), (53.9), and (53.10) including, but not limited to, | 20 | | 25I-NBOMe and 25C-NBOMe; | 21 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; | 22 | | (55) (Blank); | 23 | | (56) (Blank); | 24 | | (57) (Blank); | 25 | | (58) (Blank); | 26 | | (59) (Blank); 3-cyclopropoylindole with substitution |
| | | SB1987 | - 39 - | LRB103 25792 RLC 57149 b |
|
| 1 | | at the nitrogen atom of the indole ring by alkyl, | 2 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 3 | | aryl halide, alkyl aryl halide, | 4 | | 1-(N-methyl-2-piperidinyl)methyl, or | 5 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 6 | | on the indole ring to any extent, whether or not | 7 | | substituted on the cyclopropyl ring to any extent: | 8 | | including, but not limited to, XLR11, UR144, FUB-144; | 9 | | (60) (Blank); 3-adamantoylindole with substitution at | 10 | | the nitrogen atom of the indole ring by alkyl, haloalkyl, | 11 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 12 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 13 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 14 | | on the indole ring to any extent, whether or not | 15 | | substituted on the adamantyl ring to any extent: | 16 | | including, but not limited to, AB-001; | 17 | | (61) (Blank); N-(adamantyl)-indole-3-carboxamide with | 18 | | substitution at the nitrogen atom of the indole ring by | 19 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 20 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 21 | | 1-(N-methyl-2-piperidinyl)methyl, or | 22 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 23 | | on the indole ring to any extent, whether or not | 24 | | substituted on the adamantyl ring to any extent: | 25 | | including, but not limited to, APICA/2NE-1, STS-135; | 26 | | (62) (Blank); N-(adamantyl)-indazole-3-carboxamide |
| | | SB1987 | - 40 - | LRB103 25792 RLC 57149 b |
|
| 1 | | with substitution at a nitrogen atom of the indazole ring | 2 | | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 3 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 4 | | 1-(N-methyl-2-piperidinyl)methyl, or | 5 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 6 | | on the indazole ring to any extent, whether or not | 7 | | substituted on the adamantyl ring to any extent: | 8 | | including, but not limited to, AKB48, 5F-AKB48; | 9 | | (63) (Blank); 1H-indole-3-carboxylic acid | 10 | | 8-quinolinyl ester with substitution at the nitrogen atom | 11 | | of the indole ring by alkyl, haloalkyl, alkenyl, | 12 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 13 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 14 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 15 | | on the indole ring to any extent, whether or not | 16 | | substituted on the quinoline ring to any extent: | 17 | | including, but not limited to, PB22, 5F-PB22, FUB-PB-22; | 18 | | (64) (Blank); 3-(1-naphthoyl)indazole with | 19 | | substitution at the nitrogen atom of the indazole ring by | 20 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 21 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 22 | | 1-(N-methyl-2-piperidinyl)methyl, or | 23 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 24 | | on the indazole ring to any extent, whether or not | 25 | | substituted on the naphthyl ring to any extent: including, | 26 | | but not limited to, THJ-018, THJ-2201; |
| | | SB1987 | - 41 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (65) (Blank); 2-(1-naphthoyl)benzimidazole with | 2 | | substitution at the nitrogen atom of the benzimidazole | 3 | | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 4 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 5 | | 1-(N-methyl-2-piperidinyl)methyl, or | 6 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 7 | | on the benzimidazole ring to any extent, whether or not | 8 | | substituted on the naphthyl ring to any extent: including, | 9 | | but not limited to, FUBIMINA; | 10 | | (66) (Blank); | 11 | | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | 12 | | 3-carboxamide with substitution on the nitrogen atom of | 13 | | the indazole ring by alkyl, haloalkyl, alkenyl, | 14 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 15 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 16 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 17 | | on the indazole ring to any extent: including, but not | 18 | | limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | 19 | | (67) (Blank); | 20 | | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | 21 | | indazole-3-carboxamide with substitution on the nitrogen | 22 | | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | 23 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 24 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 25 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 26 | | on the indazole ring to any extent: including, but not |
| | | SB1987 | - 42 - | LRB103 25792 RLC 57149 b |
|
| 1 | | limited to, ADB-PINACA, ADB-FUBINACA; | 2 | | (68) (Blank); | 3 | | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | 4 | | indole-3-carboxamide with substitution on the nitrogen | 5 | | atom of the indole ring by alkyl, haloalkyl, alkenyl, | 6 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 7 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 9 | | on the indole ring to any extent: including, but not | 10 | | limited to, ADBICA, 5F-ADBICA; | 11 | | (69) (Blank); | 12 | | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | 13 | | 3-carboxamide with substitution on the nitrogen atom of | 14 | | the indole ring by alkyl, haloalkyl, alkenyl, | 15 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 16 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 18 | | on the indole ring to any extent: including, but not | 19 | | limited to, ABICA, 5F-ABICA; | 20 | | (70) (Blank); Methyl 2-(1H-indazole-3-carboxamido)-3- | 21 | | methylbutanoate with substitution on the nitrogen atom of | 22 | | the indazole ring by alkyl, haloalkyl, alkenyl, | 23 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 24 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 25 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 26 | | on the indazole ring to any extent: including, but not |
| | | SB1987 | - 43 - | LRB103 25792 RLC 57149 b |
|
| 1 | | limited to, AMB, 5F-AMB; | 2 | | (71) (Blank); | 3 | | Methyl 2-(1H-indazole-3-carboxamido)-3,3- | 4 | | dimethylbutanoate with substitution on the nitrogen
atom | 5 | | of the indazole ring by alkyl, haloalkyl, alkenyl,
| 6 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
aryl | 7 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further substituted
| 9 | | on the indazole ring to any extent: including, but not
| 10 | | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | 11 | | (72) (Blank); Methyl 2-(1H-indole-3-carboxamido)-3- | 12 | | methylbutanoate with substitution on the nitrogen atom
of | 13 | | the indole ring by alkyl, haloalkyl, alkenyl,
| 14 | | cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl | 15 | | halide, 1-(N-methyl-2-piperidinyl)methyl,
or | 16 | | 2-(4-morpholinyl)ethyl, whether or not further
substituted | 17 | | on the indazole ring to any extent:
including, but not | 18 | | limited to, MMB018, MMB2201,
and AMB-CHMICA; | 19 | | (73) (Blank); Methyl 2-(1H-indole-3-carboxamido)-3,3- | 20 | | dimethylbutanoate with substitution
on the nitrogen atom | 21 | | of the indole ring by alkyl,
haloalkyl, alkenyl, | 22 | | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | 23 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 24 | | 2-(4-morpholinyl)ethyl,
whether or not further substituted | 25 | | on the
indazole ring to any extent: including, but
not | 26 | | limited to, MDMB-CHMICA; |
| | | SB1987 | - 44 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (74) (Blank); | 2 | | N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | 3 | | indazole-3-carboxamide with
substitution on the nitrogen | 4 | | atom of the indazole
ring by alkyl, haloalkyl, alkenyl, | 5 | | cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl | 6 | | halide,
1-(N-methyl-2-piperidinyl)methyl, or | 7 | | 2-(4-morpholinyl)ethyl, whether or not further
substituted | 8 | | on the indazole ring to any
extent: including, but not | 9 | | limited to, APP-CHMINACA,
5-fluoro-APP-PINACA; | 10 | | (75) (Blank); | 11 | | N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- | 12 | | 3-carboxamide with substitution on
the nitrogen atom of | 13 | | the indole ring by alkyl,
haloalkyl, alkenyl, | 14 | | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | 15 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 16 | | 2-(4-morpholinyl)ethyl,
whether or not further substituted | 17 | | on the indazole
ring to any extent: including, but not | 18 | | limited to,
APP-PICA and 5-fluoro-APP-PICA; | 19 | | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | 20 | | 4-AcO-DMT; | 21 | | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | 22 | | name 5-MeO-MIPT; | 23 | | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | 24 | | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | 25 | | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | 26 | | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
|
| | | SB1987 | - 45 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (4-HO-MiPT); | 2 | | (82) (Blank); Fluorophenylpiperazine; | 3 | | (83) Methoxetamine; | 4 | | (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | 5 | | ethcathinone). | 6 | | (e) Unless specifically excepted or unless listed in | 7 | | another
schedule, any material, compound, mixture, or | 8 | | preparation which contains
any quantity of the following | 9 | | substances having a depressant effect on
the central nervous | 10 | | system, including its salts, isomers, and salts of
isomers | 11 | | whenever the existence of such salts, isomers, and salts of
| 12 | | isomers is possible within the specific chemical designation: | 13 | | (1) mecloqualone; | 14 | | (2) methaqualone; and | 15 | | (3) gamma hydroxybutyric acid. | 16 | | (f) Unless specifically excepted or unless listed in | 17 | | another schedule,
any material, compound, mixture, or | 18 | | preparation which contains any quantity
of the following | 19 | | substances having a stimulant effect on the central nervous
| 20 | | system, including its salts, isomers, and salts of isomers: | 21 | | (1) Fenethylline; | 22 | | (2) N-ethylamphetamine; | 23 | | (3) Aminorex (some other names:
| 24 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 25 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| 26 | | salts, optical isomers, and salts of optical isomers; |
| | | SB1987 | - 46 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (4) Methcathinone (some other names:
| 2 | | 2-methylamino-1-phenylpropan-1-one;
| 3 | | Ephedrone; 2-(methylamino)-propiophenone;
| 4 | | alpha-(methylamino)propiophenone; N-methylcathinone;
| 5 | | methycathinone; Monomethylpropion; UR 1431) and its
| 6 | | salts, optical isomers, and salts of optical isomers; | 7 | | (5) Cathinone (some trade or other names:
| 8 | | 2-aminopropiophenone; alpha-aminopropiophenone;
| 9 | | 2-amino-1-phenyl-propanone; norephedrone); | 10 | | (6) N,N-dimethylamphetamine (also known as:
| 11 | | N,N-alpha-trimethyl-benzeneethanamine;
| 12 | | N,N-alpha-trimethylphenethylamine); | 13 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 14 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | 15 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV); | 16 | | (9) Halogenated amphetamines and
| 17 | | methamphetamines - any compound derived from either
| 18 | | amphetamine or methamphetamine through the substitution
| 19 | | of a halogen on the phenyl ring, including, but not
| 20 | | limited to, 2-fluoroamphetamine, 3-
| 21 | | fluoroamphetamine and 4-fluoroamphetamine; | 22 | | (10) Aminopropylbenzofuran (APB):
| 23 | | including 4-(2-Aminopropyl) benzofuran, 5-
| 24 | | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| 25 | | benzofuran, and 7-(2-Aminopropyl) benzofuran; | 26 | | (11) Aminopropyldihydrobenzofuran (APDB):
|
| | | SB1987 | - 47 - | LRB103 25792 RLC 57149 b |
|
| 1 | | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| 2 | | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| 3 | | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
| 4 | | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | 5 | | (12) Methylaminopropylbenzofuran
| 6 | | (MAPB): including 4-(2-methylaminopropyl)
| 7 | | benzofuran, 5-(2-methylaminopropyl)benzofuran,
| 8 | | 6-(2-methylaminopropyl)benzofuran
| 9 | | and 7-(2-methylaminopropyl)benzofuran ; . | 10 | | (13 Methylaminopropyldihydrobenzofuran (MAPDB): | 11 | | including: | 12 | | 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine; | 13 | | (g) Temporary listing of substances subject to emergency | 14 | | scheduling.
Any material, compound, mixture, or preparation | 15 | | that contains any quantity
of the following substances: | 16 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| 17 | | (benzylfentanyl), its optical isomers, isomers, salts,
and | 18 | | salts of isomers; | 19 | | (2) N-[1(2-thienyl)
methyl-4-piperidyl]-N- | 20 | | phenylpropanamide (thenylfentanyl),
its optical isomers, | 21 | | salts, and salts of isomers. | 22 | | (h) Synthetic cathinones. Unless specifically excepted, | 23 | | any chemical compound which is not approved by the United | 24 | | States Food and Drug Administration or, if approved, is not | 25 | | dispensed or possessed in accordance with State or federal | 26 | | law, not including bupropion, structurally derived from |
| | | SB1987 | - 48 - | LRB103 25792 RLC 57149 b |
|
| 1 | | 2-aminopropan-1-one by substitution at the 1-position with | 2 | | either phenyl, naphthyl, or thiophene ring systems, whether or | 3 | | not the compound is further modified in one or more of the | 4 | | following ways: | 5 | | (1) by substitution in the ring system to any extent | 6 | | with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | 7 | | halide substituents, whether or not further substituted in | 8 | | the ring system by one or more other univalent | 9 | | substituents. Examples of this class include, but are not | 10 | | limited to, 3,4-Methylenedioxycathinone (bk-MDA); | 11 | | (2) by substitution at the 3-position with an acyclic | 12 | | alkyl substituent. Examples of this class include, but are | 13 | | not limited to, 2-methylamino-1-phenylbutan-1-one | 14 | | (buphedrone); or | 15 | | (3) by substitution at the 2-amino nitrogen atom with | 16 | | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by | 17 | | inclusion of the 2-amino nitrogen atom in a cyclic | 18 | | structure. Examples of this class include, but are not | 19 | | limited to, Dimethylcathinone, Ethcathinone, and | 20 | | a-Pyrrolidinopropiophenone (a-PPP); or | 21 | | Any other synthetic cathinone which is not approved by the | 22 | | United States Food and Drug Administration or, if approved, is | 23 | | not dispensed or possessed in accordance with State or federal | 24 | | law. | 25 | | (i) Synthetic cannabinoids or piperazines. Any synthetic | 26 | | cannabinoid or piperazine which is not approved by the United |
| | | SB1987 | - 49 - | LRB103 25792 RLC 57149 b |
|
| 1 | | States Food and Drug Administration or, if approved, which is | 2 | | not dispensed or possessed in accordance with State and | 3 | | federal law. | 4 | | (1) Synthetic cannabinoids include, but are not | 5 | | limited to, compounds as identified in a report from an | 6 | | accredited forensic laboratory, which are structurally | 7 | | derived from the following compounds: | 8 | | (1.1) 3-(1-naphthoyl)indole or | 9 | | 1H-indol-3-yl-(1-naphthyl)methane by substitution at | 10 | | the nitrogen atom of the indole ring by alkyl, | 11 | | haloalkyl, alkenyl, cycloalkylmethyl, | 12 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 13 | | 1-(N-methyl-2-piperidinyl)methyl, or | 14 | | 2-(4-morpholinyl)ethyl whether or not further | 15 | | substituted in the indole ring to any extent, whether | 16 | | or not substituted in the naphthyl ring to any extent. | 17 | | Examples of this structural class include, but are not | 18 | | limited to, JWH-018, AM-2201, JWH-175, JWH-184, and | 19 | | JWH-185; | 20 | | (1.2) 3-(1-naphthoyl)pyrrole by substitution at | 21 | | the nitrogen atom of the pyrrole ring by alkyl, | 22 | | haloalkyl, alkenyl, cycloalkylmethyl, | 23 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 24 | | 1-(N-methyl-2-piperidinyl)methyl, or | 25 | | 2-(4-morpholinyl)ethyl, whether or not further | 26 | | substituted in the pyrrole ring to any extent, whether |
| | | SB1987 | - 50 - | LRB103 25792 RLC 57149 b |
|
| 1 | | or not substituted in the naphthyl ring to any extent. | 2 | | Examples of this structural class include, but are not | 3 | | limited to, JWH-030, JWH-145, JWH-146, JWH-307, and | 4 | | JWH-368; | 5 | | (1.3) Any compound structurally derived from | 6 | | 1-(1-naphthylmethyl)indene by substitution at the | 7 | | 3-position of the indene ring by alkyl, haloalkyl, | 8 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 9 | | halide, alkyl aryl halide, | 10 | | 1-(N-methyl-2-piperidinyl)methyl, or | 11 | | 2-(4-morpholinyl)ethyl whether or not further | 12 | | substituted in the indene ring to any extent, whether | 13 | | or not substituted in the naphthyl ring to any extent. | 14 | | Examples of this structural class include, but are not | 15 | | limited to, JWH-176; | 16 | | (1.4) Any compound structurally derived from | 17 | | 3-phenylacetylindole by substitution at the nitrogen | 18 | | atom of the indole ring with alkyl, haloalkyl, | 19 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 20 | | halide, alkyl aryl halide, | 21 | | 1-(N-methyl-2-piperidinyl)methyl, or | 22 | | 2-(4-morpholinyl)ethyl, whether or not further | 23 | | substituted in the indole ring to any extent, whether | 24 | | or not substituted in the phenyl ring to any extent. | 25 | | Examples of this structural class include, but are not | 26 | | limited to, JWH-167, JWH-250, JWH-251, and RCS-8; |
| | | SB1987 | - 51 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (1.5) Any compound structurally derived from | 2 | | 2-(3-hydroxycyclohexyl)phenol by substitution at the | 3 | | 5-position of the phenolic ring by alkyl, haloalkyl, | 4 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 5 | | halide, alkyl aryl halide, | 6 | | 1-(N-methyl-2-piperidinyl)methyl, or | 7 | | 2-(4-morpholinyl)ethyl, whether or not substituted in | 8 | | the cyclohexyl ring to any extent. Examples of this | 9 | | structural class include, but are not limited to, CP | 10 | | 47, 497 and its C8 homologue (cannabicyclohexanol); | 11 | | (1.6) Any compound structurally derived from | 12 | | 3-(benzoyl) indole with substitution at the nitrogen | 13 | | atom of the indole ring by an alkyl, haloalkyl, | 14 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 15 | | halide, alkyl aryl halide, | 16 | | 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl group whether or not further | 18 | | substituted in the indole ring to any extent and | 19 | | whether or not substituted in the phenyl ring to any | 20 | | extent. Examples of this structural class include, but | 21 | | are not limited to, AM-630, AM-2233, AM-694, | 22 | | Pravadoline (WIN 48,098), and RCS-4; | 23 | | (1.7) 3-cyclopropoylindole with substitution at | 24 | | the nitrogen atom of the indole ring by alkyl, | 25 | | haloalkyl, alkenyl, cycloalkylmethyl, | 26 | | cycloalkylethyl, aryl halide, alkyl aryl halide, |
| | | SB1987 | - 52 - | LRB103 25792 RLC 57149 b |
|
| 1 | | 1-(N-methyl-2-piperidinyl)methyl, or | 2 | | 2-(4-morpholinyl)ethyl, whether or not further | 3 | | substituted on the indole ring to any extent, whether | 4 | | or not substituted on the cyclopropyl ring to any | 5 | | extent: including, but not limited to, XLR11, UR144, | 6 | | FUB-144; | 7 | | (1.8) 3-adamantoylindole with substitution at the | 8 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 9 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 10 | | halide, alkyl aryl halide, | 11 | | 1-(N-methyl-2-piperidinyl)methyl, or | 12 | | 2-(4-morpholinyl)ethyl, whether or not further | 13 | | substituted on the indole ring to any extent, whether | 14 | | or not substituted on the adamantyl ring to any | 15 | | extent: including, but not limited to, AB-001; | 16 | | (1.9) N-(adamantyl)-indole-3-carboxamide with | 17 | | substitution at the nitrogen atom of the indole ring | 18 | | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 19 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 20 | | 1-(N-methyl-2-piperidinyl)methyl, or | 21 | | 2-(4-morpholinyl)ethyl, whether or not further | 22 | | substituted on the indole ring to any extent, whether | 23 | | or not substituted on the adamantyl ring to any | 24 | | extent: including, but not limited to, APICA/2NE-1, | 25 | | STS-135; | 26 | | (1.10) N-(adamantyl)-indazole-3-carboxamide with |
| | | SB1987 | - 53 - | LRB103 25792 RLC 57149 b |
|
| 1 | | substitution at a nitrogen atom of the indazole ring | 2 | | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 3 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 4 | | 1-(N-methyl-2-piperidinyl)methyl, or | 5 | | 2-(4-morpholinyl)ethyl, whether or not further | 6 | | substituted on the indazole ring to any extent, | 7 | | whether or not substituted on the adamantyl ring to | 8 | | any extent: including, but not limited to, AKB48, | 9 | | 5F-AKB48; | 10 | | (1.11) 1H-indole-3-carboxylic acid 8-quinolinyl | 11 | | ester with substitution at the nitrogen atom of the | 12 | | indole ring by alkyl, haloalkyl, alkenyl, | 13 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl | 14 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 15 | | 2-(4-morpholinyl)ethyl, whether or not further | 16 | | substituted on the indole ring to any extent, whether | 17 | | or not substituted on the quinoline ring to any | 18 | | extent: including, but not limited to, PB22, 5F-PB22, | 19 | | FUB-PB-22; | 20 | | (1.12) 3-(1-naphthoyl)indazole with substitution | 21 | | at the nitrogen atom of the indazole ring by alkyl, | 22 | | haloalkyl, alkenyl, cycloalkylmethyl, | 23 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 24 | | 1-(N-methyl-2-piperidinyl)methyl, or | 25 | | 2-(4-morpholinyl)ethyl, whether or not further | 26 | | substituted on the indazole ring to any extent, |
| | | SB1987 | - 54 - | LRB103 25792 RLC 57149 b |
|
| 1 | | whether or not substituted on the naphthyl ring to any | 2 | | extent: including, but not limited to, THJ-018, | 3 | | THJ-2201; | 4 | | (1.13) 2-(1-naphthoyl)benzimidazole with | 5 | | substitution at the nitrogen atom of the benzimidazole | 6 | | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 7 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 8 | | 1-(N-methyl-2-piperidinyl)methyl, or | 9 | | 2-(4-morpholinyl)ethyl, whether or not further | 10 | | substituted on the benzimidazole ring to any extent, | 11 | | whether or not substituted on the naphthyl ring to any | 12 | | extent: including, but not limited to, FUBIMINA; | 13 | | (1.14) N-(1-amino-3-methyl-1-oxobutan-2-yl)- | 14 | | 1H-indazole-3-carboxamide with substitution on the | 15 | | nitrogen atom of the indazole ring by alkyl, | 16 | | haloalkyl, alkenyl, cycloalkylmethyl, | 17 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 18 | | 1-(N-methyl-2-piperidinyl)methyl, or | 19 | | 2-(4-morpholinyl)ethyl, whether or not further | 20 | | substituted on the indazole ring to any extent: | 21 | | including, but not limited to, AB-PINACA, AB-FUBINACA, | 22 | | AB-CHMINACA; | 23 | | (1.15) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- | 24 | | 1H-indazole-3-carboxamide with substitution on the | 25 | | nitrogen atom of the indazole ring by alkyl, | 26 | | haloalkyl, alkenyl, cycloalkylmethyl, |
| | | SB1987 | - 55 - | LRB103 25792 RLC 57149 b |
|
| 1 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 2 | | 1-(N-methyl-2-piperidinyl)methyl, or | 3 | | 2-(4-morpholinyl)ethyl, whether or not further | 4 | | substituted on the indazole ring to any extent: | 5 | | including, but not limited to, ADB-PINACA, | 6 | | ADB-FUBINACA; | 7 | | (1.16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- | 8 | | 1H-indole-3-carboxamide with substitution on the | 9 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 10 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 11 | | halide, alkyl aryl halide, | 12 | | 1-(N-methyl-2-piperidinyl)methyl, or | 13 | | 2-(4-morpholinyl)ethyl, whether or not further | 14 | | substituted on the indole ring to any extent: | 15 | | including, but not limited to, ADBICA, 5F-ADBICA; | 16 | | (1.17) N-(1-amino-3-methyl-1-oxobutan-2-yl)- | 17 | | 1H-indole-3-carboxamide with substitution on the | 18 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 19 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 20 | | halide, alkyl aryl halide, | 21 | | 1-(N-methyl-2-piperidinyl)methyl, or | 22 | | 2-(4-morpholinyl)ethyl, whether or not further | 23 | | substituted on the indole ring to any extent: | 24 | | including, but not limited to, ABICA, 5F-ABICA; | 25 | | (1.18) Methyl 2-(1H-indazole-3-carboxamido)- | 26 | | 3-methylbutanoate with substitution on the nitrogen |
| | | SB1987 | - 56 - | LRB103 25792 RLC 57149 b |
|
| 1 | | atom of the indazole ring by alkyl, haloalkyl, | 2 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 3 | | halide, alkyl aryl halide, | 4 | | 1-(N-methyl-2-piperidinyl)methyl, or | 5 | | 2-(4-morpholinyl)ethyl, whether or not further | 6 | | substituted on the indazole ring to any extent: | 7 | | including, but not limited to, AMB, 5F-AMB; | 8 | | (1.19) Methyl 2-(1H-indazole-3-carboxamido)- | 9 | | 3,3-dimethylbutanoate with substitution on the | 10 | | nitrogen atom of the indazole ring by alkyl, | 11 | | haloalkyl, alkenyl, cycloalkylmethyl, | 12 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 13 | | 1-(N-methyl-2-piperidinyl)methyl, or | 14 | | 2-(4-morpholinyl)ethyl, whether or not further | 15 | | substituted on the indazole ring to any extent: | 16 | | including, but not limited to, 5-fluoro-MDMB-PINACA, | 17 | | MDMB-FUBINACA; | 18 | | (1.20) Methyl | 19 | | 2-(1H-indole-3-carboxamido)-3-methylbutanoate with | 20 | | substitution on the nitrogen atom of the indole ring | 21 | | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 22 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 23 | | 1-(N-methyl-2-piperidinyl)methyl, or | 24 | | 2-(4-morpholinyl)ethyl, whether or not further | 25 | | substituted on the indole ring to any extent: | 26 | | including, but not limited to, MMB018, MMB2201, and |
| | | SB1987 | - 57 - | LRB103 25792 RLC 57149 b |
|
| 1 | | AMB-CHMICA; | 2 | | (1.21) Methyl 2-(1H-indole-3-carboxamido)- | 3 | | 3,3-dimethylbutanoate with substitution on the | 4 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 5 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 6 | | halide, alkyl aryl halide, | 7 | | 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further | 9 | | substituted on the indole ring to any extent: | 10 | | including, but not limited to, MDMB-CHMICA; | 11 | | (1.22) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)- | 12 | | 1H-indazole-3-carboxamide with substitution on the | 13 | | nitrogen atom of the indazole ring by alkyl, | 14 | | haloalkyl, alkenyl, cycloalkylmethyl, | 15 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 16 | | 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further | 18 | | substituted on the indazole ring to any extent: | 19 | | including, but not limited to, APP-CHMINACA, | 20 | | 5-fluoro-APP-PINACA; | 21 | |
(1.23) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)- | 22 | | 1H-indole-3-arboxamide with substitution on the | 23 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 24 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 25 | | halide, alkyl aryl halide, | 26 | | 1-(N-methyl-2-piperidinyl)methyl, or |
| | | SB1987 | - 58 - | LRB103 25792 RLC 57149 b |
|
| 1 | | 2-(4-morpholinyl)ethyl, whether or not further | 2 | | substituted on the indole ring to any extent: | 3 | | including, but not limited to, APP-PICA and | 4 | | 5-fluoro-APP-PICA; | 5 | | (1.24) 1H-indazole-3-carboxylic acid 8-quinolinyl | 6 | | ester with substitution at the nitrogen atom of the | 7 | | indazole ring by alkyl, haloalkyl, alkenyl, | 8 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl | 9 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 10 | | 2-(4-morpholinyl)ethyl, whether or not further | 11 | | substituted on the inazdole ring to any extent, | 12 | | whether or not substituted on the quinoline ring to | 13 | | any extent: including, but not limited to, SDB-005, | 14 | | 5-F-SDB-005. | 15 | | (2) Synthetic piperazines include, but are not limited | 16 | | to the following compounds and their positional isomers: | 17 | | (2.1) N-Benzylpiperazine (BZP); | 18 | | (2.2) Trifluoromethylphenylpiperazine (TFMPP); | 19 | | (2.3) Fluorophenylpiperazine; | 20 | | (2.4) Chlorophenylpiperazine; | 21 | | (j) Fentanyl-related substances. | 22 | | (1) Fentanyl-related substance means any compound as | 23 | | identified in a report from an accredited forensic | 24 | | laboratory, unless specifically excepted or listed under | 25 | | another schedule, which is not approved by the United | 26 | | States Food and Drug Administration, or if approved, is |
| | | SB1987 | - 59 - | LRB103 25792 RLC 57149 b |
|
| 1 | | not dispensed or possessed in accordance with State or | 2 | | Federal law, that is structurally derived from fentanyl | 3 | | (N-phenyl-N-(1-(2-phenylethyl)-4- | 4 | | piperidinyl)-propanamide) by one or more of the following | 5 | | modifications: | 6 | | (A) Replacement of the phenyl portion of the | 7 | | phenethyl group by any monocycle, whether or not | 8 | | further substituted in or on the monocycle; | 9 | | (B) Substitution in or on the phenethyl group with | 10 | | alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, | 11 | | amino or nitro groups; | 12 | | (C) Substitution in or on the piperidine ring with | 13 | | alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, | 14 | | haloalkyl, amino or nitro groups; | 15 | | (D) Replacement of the aniline ring with any | 16 | | aromatic monocycle whether or not further substituted | 17 | | in or on the aromatic monocycle; | 18 | | (E) Replacement of the N-propionyl group by | 19 | | another acyl group. | 20 | | (2) This definition includes, but is not limited to, | 21 | | the following substances: | 22 | | (2.1) Acetyl-alpha-methylfentanyl. | 23 | | (2.2) Alpha-methylfentanyl
(N-(1-alpha-methyl- | 24 | | beta-phenyl) ethyl-4-piperidyl)
propionanilide; | 25 | | 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine; | 26 | | (2.3) Alpha-methylthiofentanyl
(N-[1-methyl-2- |
| | | SB1987 | - 60 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide); | 2 | | (2.4) Beta-hydroxyfentanyl
(N-[1-(2-hydroxy-2- | 3 | | phenethyl)-4-piperidinyl]-N-phenylpropanamide; | 4 | | (2.5) 3-Methylfentanyl
(N-[3-methyl-1- | 5 | | (2-phenylethyl)-4-piperidyl]-N-phenylpropanamide); | 6 | | (2.6) 3-Methylthiofentanyl
(N-[(3-methyl-1- | 7 | | (2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide); | 8 | | (2.7) Para-fluorofentanyl
(N-(4-fluorophenyl)- | 9 | | N-[1-(2-phenethyl)-4-piperidinyl]propanamide); | 10 | | (2.8) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl- | 11 | | 4-piperidinyl]-propanamide); | 12 | | (2.9) Beta-hydroxy-3-methylfentanyl (other name:
| 13 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 14 | | N-phenylpropanamide); | 15 | | (2.10) Furanyl fentanyl (FU-F); | 16 | | (2.11) Butyryl fentanyl; | 17 | | (2.12) Valeryl fentanyl; | 18 | | (2.13) Acetyl fentanyl; | 19 | | (2.14) Beta-hydroxy-thiofentanyl; | 20 | | (2.15) Acrylfentanyl (acryloylfentanyl); | 21 | | (2.16) Cyclopropyl fentanyl; | 22 | | (2.17) Crotonyl fentanyl; | 23 | | (2.18) Methoxyacetyl fentanyl; | 24 | | (2.19) Pentanoyl fentanyl; | 25 | | (2.20) Cyclopentyl fentanyl; | 26 | | (2.21) Isobutyryl fentanyl; |
| | | SB1987 | - 61 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (2.22) Benzodioxolefentanyl; | 2 | | (2.23) Tetrahydrofuran fentanyl. | 3 | | (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; | 4 | | 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. | 5 | | 8-14-18 .)
| 6 | | (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
| 7 | | Sec. 206. (a) The controlled substances listed in this | 8 | | Section are
included in Schedule II.
| 9 | | (b) Unless specifically excepted or unless listed in | 10 | | another
schedule, any of the following substances whether | 11 | | produced directly or
indirectly by extraction from substances | 12 | | of vegetable origin, or
independently by means of chemical | 13 | | synthesis, or by combination of
extraction and chemical | 14 | | synthesis:
| 15 | | (1) Opium and opiates, and any salt, compound, | 16 | | derivative or
preparation of opium or opiate, excluding | 17 | | apomorphine, dextrorphan,
levopropoxyphene,
nalbuphine, | 18 | | nalmefene, naloxone, and naltrexone, and their respective
| 19 | | salts, but including the following:
| 20 | | (i) Raw Opium;
| 21 | | (ii) Opium extracts;
| 22 | | (iii) Opium fluid extracts;
| 23 | | (iv) Powdered opium;
| 24 | | (v) Granulated opium;
| 25 | | (vi) Tincture of opium;
|
| | | SB1987 | - 62 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (vii) Codeine;
| 2 | | (viii) Ethylmorphine;
| 3 | | (ix) Etorphine Hydrochloride;
| 4 | | (x) Hydrocodone;
| 5 | | (xi) Hydromorphone;
| 6 | | (xii) Metopon;
| 7 | | (xiii) Morphine;
| 8 | | (xiii.5) 6-Monoacetylmorphine; | 9 | | (xiv) Oxycodone;
| 10 | | (xv) Oxymorphone;
| 11 | | (xv.5) Tapentadol; | 12 | | (xvi) Thebaine;
| 13 | | (xvii) Thebaine-derived butorphanol.
| 14 | | (xviii) Methorphan, except drug products | 15 | | containing dextromethorphan that may be dispensed | 16 | | pursuant to a prescription order of a practitioner and | 17 | | are sold in compliance with the safety and labeling | 18 | | standards as set forth by the United States Food and | 19 | | Drug Administration, or drug products containing | 20 | | dextromethorphan that are sold in solid, tablet, | 21 | | liquid, capsule, powder, thin film, or gel form and | 22 | | which are formulated, packaged, and sold in dosages | 23 | | and concentrations for use as an over-the-counter drug | 24 | | product. For the purposes of this Section, | 25 | | "over-the-counter drug product" means a drug that is | 26 | | available to consumers without a prescription and sold |
| | | SB1987 | - 63 - | LRB103 25792 RLC 57149 b |
|
| 1 | | in compliance with the safety and labeling standards | 2 | | as set forth by the United States Food and Drug | 3 | | Administration.
| 4 | | (2) Any salt, compound, isomer, derivative or | 5 | | preparation thereof
which is chemically equivalent or | 6 | | identical with any of the substances
referred to in | 7 | | subparagraph (1), but not including the isoquinoline
| 8 | | alkaloids of opium;
| 9 | | (3) Opium poppy and poppy straw;
| 10 | | (4) Coca leaves and any salt, compound, isomer, salt | 11 | | of an isomer,
derivative, or preparation of coca leaves | 12 | | including cocaine or ecgonine,
and any salt, compound, | 13 | | isomer, derivative, or preparation thereof which is
| 14 | | chemically equivalent or identical with any of these | 15 | | substances, but not
including decocainized coca leaves or | 16 | | extractions of coca leaves which do
not contain cocaine or | 17 | | ecgonine (for the purpose of this paragraph, the
term | 18 | | "isomer" includes optical , positional and geometric | 19 | | isomers);
| 20 | | (5) Concentrate of poppy straw (the crude extract of | 21 | | poppy straw in
either liquid, solid or powder form which | 22 | | contains the phenanthrine
alkaloids of the opium poppy).
| 23 | | (c) Unless specifically excepted or unless listed in | 24 | | another
schedule any of the following opiates, including their | 25 | | isomers, esters,
ethers, salts, and salts of isomers, whenever | 26 | | the existence of these
isomers, esters, ethers and salts is |
| | | SB1987 | - 64 - | LRB103 25792 RLC 57149 b |
|
| 1 | | possible within the specific
chemical designation, dextrorphan | 2 | | excepted:
| 3 | | (1) Alfentanil;
| 4 | | (1.1) Carfentanil;
| 5 | | (1.2) Thiafentanyl; | 6 | | (2) Alphaprodine;
| 7 | | (3) Anileridine;
| 8 | | (4) Bezitramide;
| 9 | | (5) Bulk Dextropropoxyphene (non-dosage forms);
| 10 | | (6) Dihydrocodeine;
| 11 | | (7) Diphenoxylate;
| 12 | | (8) Fentanyl;
| 13 | | (9) Sufentanil;
| 14 | | (9.5) Remifentanil;
| 15 | | (10) Isomethadone;
| 16 | | (11) (Blank);
| 17 | | (12) Levorphanol (Levorphan);
| 18 | | (13) Metazocine;
| 19 | | (14) Methadone;
| 20 | | (15) Methadone-Intermediate,
| 21 | | 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
| 22 | | (16) Moramide-Intermediate,
| 23 | | 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
| 24 | | acid;
| 25 | | (17) Pethidine (meperidine);
| 26 | | (18) Pethidine-Intermediate-A,
|
| | | SB1987 | - 65 - | LRB103 25792 RLC 57149 b |
|
| 1 | | 4-cyano-1-methyl-4-phenylpiperidine;
| 2 | | (19) Pethidine-Intermediate-B,
| 3 | | ethyl-4-phenylpiperidine-4-carboxylate;
| 4 | | (20) Pethidine-Intermediate-C,
| 5 | | 1-methyl-4-phenylpiperidine-4-carboxylic acid;
| 6 | | (21) Phenazocine;
| 7 | | (22) Piminodine;
| 8 | | (23) Racemethorphan;
| 9 | | (24) (Blank);
| 10 | | (25) Levo-alphacetylmethadol (some other names:
| 11 | | levo-alpha-acetylmethadol,
levomethadyl acetate, LAAM).
| 12 | | (d) Unless specifically excepted or unless listed in | 13 | | another
schedule, any material, compound, mixture, or | 14 | | preparation which contains
any quantity of the following | 15 | | substances having a stimulant effect on
the central nervous | 16 | | system:
| 17 | | (1) Amphetamine, its salts, optical isomers, and salts | 18 | | of its
optical isomers;
| 19 | | (2) Methamphetamine, its salts, isomers, and salts of | 20 | | its isomers;
| 21 | | (3) Phenmetrazine and its salts;
| 22 | | (4) Methylphenidate;
| 23 | | (5) Lisdexamfetamine. | 24 | | (e) Unless specifically excepted or unless listed in | 25 | | another
schedule, any material, compound, mixture, or | 26 | | preparation which contains
any quantity of the following |
| | | SB1987 | - 66 - | LRB103 25792 RLC 57149 b |
|
| 1 | | substances having a depressant effect on
the central nervous | 2 | | system, including its salts, isomers, and salts of
isomers | 3 | | whenever the existence of such salts, isomers, and salts of
| 4 | | isomers is possible within the specific chemical designation:
| 5 | | (1) Amobarbital;
| 6 | | (2) Secobarbital;
| 7 | | (3) Pentobarbital;
| 8 | | (4) Pentazocine;
| 9 | | (5) Phencyclidine;
| 10 | | (6) Gluthethimide;
| 11 | | (7) (Blank).
| 12 | | (f) Unless specifically excepted or unless listed in | 13 | | another schedule,
any material, compound, mixture, or | 14 | | preparation which contains any quantity
of the following | 15 | | substances:
| 16 | | (1) Immediate precursor to amphetamine and | 17 | | methamphetamine:
| 18 | | (i) Phenylacetone
| 19 | | Some trade or other names: phenyl-2-propanone;
| 20 | | P2P; benzyl methyl ketone; methyl benzyl ketone.
| 21 | | (2) Immediate precursors to phencyclidine:
| 22 | | (i) 1-phenylcyclohexylamine;
| 23 | | (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
| 24 | | (3) Nabilone.
| 25 | | (Source: P.A. 100-368, eff. 1-1-18 .)
|
| | | SB1987 | - 67 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (720 ILCS 570/210) (from Ch. 56 1/2, par. 1210)
| 2 | | Sec. 210.
(a) The controlled substances listed in this | 3 | | Section are
included in Schedule IV.
| 4 | | (b) Unless specifically excepted or unless listed in | 5 | | another schedule,
any material, compound, mixture, or | 6 | | preparation containing limited quantities
of any of the | 7 | | following narcotic drugs, or their salts calculated as the
| 8 | | free anhydrous base or alkaloid, as set forth below:
| 9 | | (1) Not more than 1 milligram of difenoxin (DEA Drug | 10 | | Code No. 9618) and
not less than 25 micrograms of atropine | 11 | | sulfate per dosage unit.
| 12 | | (2) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,
| 13 | | 2-diphenyl-3-methyl-2-propionoxybutane).
| 14 | | (c) Unless specifically excepted or unless listed in | 15 | | another
schedule, any material, compound, mixture, or | 16 | | preparation which contains
any quantity of the following | 17 | | substances having a potential for abuse
associated with a | 18 | | depressant effect on the central nervous system:
| 19 | | (1) Alprazolam;
| 20 | | (2) Barbital;
| 21 | | (2.1) Bromazepam;
| 22 | | (2.2) Camazepam;
| 23 | | (2.3) Carisoprodol;
| 24 | | (3) Chloral Betaine;
| 25 | | (4) Chloral Hydrate;
| 26 | | (5) Chlordiazepoxide;
|
| | | SB1987 | - 68 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (5.1) Clobazam;
| 2 | | (6) Clonazepam;
| 3 | | (7) Clorazepate;
| 4 | | (7.1) Clotiazepam;
| 5 | | (7.2) Cloxazolam;
| 6 | | (7.3) Delorazepam;
| 7 | | (8) Diazepam;
| 8 | | (8.05) Dichloralphenazone;
| 9 | | (8.1) Estazolam;
| 10 | | (9) Ethchlorvynol;
| 11 | | (10) Ethinamate;
| 12 | | (10.1) Ethyl loflazepate;
| 13 | | (10.2) Fludiazepam;
| 14 | | (10.3) Flunitrazepam;
| 15 | | (11) Flurazepam;
| 16 | | (11.1) Fospropofol;
| 17 | | (12) Halazepam;
| 18 | | (12.1) Haloxazolam;
| 19 | | (12.2) Ketazolam;
| 20 | | (12.3) Loprazolam;
| 21 | | (13) Lorazepam;
| 22 | | (13.1) Lormetazepam;
| 23 | | (14) Mebutamate;
| 24 | | (14.1) Medazepam;
| 25 | | (15) Meprobamate;
| 26 | | (16) Methohexital;
|
| | | SB1987 | - 69 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (17) Methylphenobarbital (Mephobarbital);
| 2 | | (17.1) Midazolam;
| 3 | | (17.2) Nimetazepam;
| 4 | | (17.3) Nitrazepam;
| 5 | | (17.4) Nordiazepam;
| 6 | | (18) Oxazepam;
| 7 | | (18.1) Oxazolam;
| 8 | | (19) Paraldehyde;
| 9 | | (20) Petrichloral;
| 10 | | (21) Phenobarbital;
| 11 | | (21.1) Pinazepam;
| 12 | | (22) Prazepam;
| 13 | | (22.1) Quazepam;
| 14 | | (23) Temazepam;
| 15 | | (23.1) Tetrazepam;
| 16 | | (23.2) Tramadol;
| 17 | | (24) Triazolam;
| 18 | | (24.5) Zaleplon;
| 19 | | (25) Zolpidem;
| 20 | | (26) Zopiclone. | 21 | | (1) Unless specifically excepted or listed in another | 22 | | schedule, any chemical compound which is not approved by | 23 | | the United States Food and Drug Administration or, if | 24 | | approved, is not dispensed or possessed in accordance with | 25 | | State or federal law, and is derived from the following | 26 | | structural classes and their salts: |
| | | SB1987 | - 70 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (A) Benzodiazepine class: A fused 1,4-diazepine | 2 | | and benzene ring structure with a phenyl connected to | 3 | | the 1,4-diazepine ring, with any substitution or | 4 | | replacement on the 1,4-diazepine or benzene ring, any | 5 | | substitution on the phenyl ring, or any combination | 6 | | thereof. This definition includes, but is not limited | 7 | | to, the following substances: | 8 | | (1.A.1) Alprazolam; | 9 | | (1.A.2) Bromazepam; | 10 | | (1.A.3) Camazepam; | 11 | | (1.A.4) Clobazam; | 12 | | (1.A.5) Clonazepam; | 13 | | (1.A.6) Clonazolam; | 14 | | (1.A.7) Clorazepate; | 15 | | (1.A.8) Delorazepam; | 16 | | (1.A.9) Diazepam; | 17 | | (1.A.10) Diclazepam; | 18 | | (1.A.11) Estazolam; | 19 | | (1.A.12) Ethyl loflazepate; | 20 | | (1.A.13) Flualprazolam; | 21 | | (1.A.14) Flubromazepam; | 22 | | (1.A.15) Flubromazolam; | 23 | | (1.A.16) Fludiazepam; | 24 | | (1.A.17) Flunitrazepam; | 25 | | (1.A.18) Flurazepam; | 26 | | (1.A.19) Halazepam; |
| | | SB1987 | - 71 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (1.A.20) Loprazolam; | 2 | | (1.A.21) Lorazepam; | 3 | | (1.A.22) Lormetazepam; | 4 | | (1.A.23) Meclonazolam; | 5 | | (1.A.24) Medazepam; | 6 | | (1.A.25) Midazolam; | 7 | | (1.A.26) Nimetazepam; | 8 | | (1.A.27) Nitrazepam; | 9 | | (1.A.28) Nordiazepam; | 10 | | (1.A.29) Oxazepam; | 11 | | (1.A.30) Pinazepam; | 12 | | (1.A.31) Prazepam; | 13 | | (1.A.32) Quazepam; | 14 | | (1.A.33) Temazepam; | 15 | | (1.A.34) Triazolam; | 16 | | (B) Thienodiazepine class: A fused 1,4-diazepine | 17 | | and thiophene ring structure with a phenyl connected | 18 | | to the 1,4-diazepine ring, with any substitution or | 19 | | replacement on the 1,4-diazepine or thiophene ring, | 20 | | any substitution(s) on the phenyl ring, or any | 21 | | combination thereof. This definition includes, but is | 22 | | not limited to, the following substances: | 23 | | (1.B.1) Clotiazepam; | 24 | | (1.B.2) Etizolam; | 25 | | (2) Barbital; | 26 | | (3) Carisoprodol; |
| | | SB1987 | - 72 - | LRB103 25792 RLC 57149 b |
|
| 1 | | (4) Chloral Betaine; | 2 | | (5) Chloral Hydrate; | 3 | | (6) Chlordiazepoxide; | 4 | | (7) Cloxazolam; | 5 | | (8) Dichloralphenazone; | 6 | | (9) Ethchlorvynol; | 7 | | (10) Ethinamate; | 8 | | (11) Fospropofol; | 9 | | (12) Haloxazolam; | 10 | | (13) Ketazolam; | 11 | | (14) Mebutamate; | 12 | | (15) Meprobamate; | 13 | | (16) Methohexital; | 14 | | (17) Methylphenobarbital (Mephobarbital); | 15 | | (18) Oxazolam; | 16 | | (19) Paraldehyde; | 17 | | (20) Petrichloral; | 18 | | (21) Phenobarbital; | 19 | | (22) Tetrazepam; | 20 | | (23) Tramadol; | 21 | | (24) Zaleplon; | 22 | | (25) Zolpidem; | 23 | | (26) Zopiclone. | 24 | | (d) Any material, compound, mixture, or preparation which | 25 | | contains
any quantity of the following substances, including | 26 | | its salts, isomers
(whether optical, position, or geometric), |
| | | SB1987 | - 73 - | LRB103 25792 RLC 57149 b |
|
| 1 | | and salts of such isomers,
whenever the existence of such | 2 | | salts, isomers and salts of isomers is
possible:
| 3 | | (1) Fenfluramine.
| 4 | | (e) Unless specifically excepted or unless listed in | 5 | | another
schedule any material, compound, mixture, or | 6 | | preparation which contains
any quantity of the following | 7 | | substances having a stimulant effect on
the central nervous | 8 | | system, including its salts, isomers (whether
optical, | 9 | | position or geometric), and salts of such isomers whenever the
| 10 | | existence of such salts, isomers, and salts of isomers is | 11 | | possible
within the specific chemical designation:
| 12 | | (1) Cathine ((+)-norpseudoephedrine);
| 13 | | (1.1) Diethylpropion;
| 14 | | (1.2) Fencamfamin;
| 15 | | (1.3) Fenproporex;
| 16 | | (2) Mazindol;
| 17 | | (2.1) Mefenorex;
| 18 | | (3) Phentermine;
| 19 | | (4) Pemoline (including organometallic complexes and | 20 | | chelates
thereof);
| 21 | | (5) Pipradrol;
| 22 | | (6) SPA ((-)-1-dimethylamino-1, 2-diphenylethane);
| 23 | | (7) Modafinil;
| 24 | | (8) Sibutramine.
| 25 | | (f) Other Substances. Unless specifically excepted or | 26 | | unless listed in
another schedule, any material,
compound,
|
| | | SB1987 | - 74 - | LRB103 25792 RLC 57149 b |
|
| 1 | | mixture, or preparation that contains any quantity of the | 2 | | following substance,
including its
salts:
| 3 | | (1) Butorphanol (including its optical isomers).
| 4 | | (g) The Department may except by rule any compound, | 5 | | mixture, or
preparation containing any depressant substance | 6 | | listed in subsection (b)
from the application of all or any | 7 | | part of this Act if the compound,
mixture, or preparation | 8 | | contains one or more active medicinal
ingredients not having a | 9 | | depressant effect on the central nervous
system, and if the | 10 | | admixtures are included therein in combinations,
quantity, | 11 | | proportion, or concentration that vitiate the potential for
| 12 | | abuse of the substances which have a depressant effect on the | 13 | | central
nervous system.
| 14 | | (h) Except as otherwise provided in Section 216, any | 15 | | material, compound,
mixture, or preparation that contains any
| 16 | | quantity of the following substance having a stimulant effect | 17 | | on the central
nervous system, including its salts, | 18 | | enantiomers (optical isomers) and salts of
enantiomers | 19 | | (optical isomers):
| 20 | | (1) Ephedrine, its salts, optical isomers and salts of | 21 | | optical isomers.
| 22 | | (Source: P.A. 97-334, eff. 1-1-12.)
|
|